Open in Screener

CSTL

Castle Biosciences Inc

Apr 02 • 04:00PM ET

24.84

-0.21 -0.84 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IWN IBB VTWO SCHA BSVO VHT DFAT

Index	RUT	P/E	-	EPS (ttm)	-0.85	Insider Own	2.65%	Shs Outstand	29.69M	Perf Week	0.57%
Market Cap	738.52M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-26.80%	Shs Float	28.94M	Perf Month	-11.82%
Enterprise Value	476.04M	PEG	-	EPS next Q	-0.49	Inst Own	92.13%	Short Float	4.94%	Perf Quarter	-36.14%
Income	-24.16M	P/S	2.15	EPS this Y	-41.52%	Inst Trans	-5.13%	Short Ratio	3.55	Perf Half Y	7.91%
Sales	344.23M	P/B	1.57	EPS next Y	53.67%	ROA	-4.15%	Short Interest	1.43M	Perf YTD	-36.14%
Book/sh	15.86	P/C	2.47	EPS next 5Y	66.94%	ROE	-5.21%	52W High	44.28 -43.90%	Perf Year	23.03%
Cash/sh	10.07	P/FCF	26.07	EPS past 3/5Y	31.36% -8.93%	ROIC	-4.77%	52W Low	14.59 70.25%	Perf 3Y	9.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	35.94% 40.60%	Gross Margin	68.66%	Volatility	4.26% 3.97%	Perf 5Y	-65.05%
Dividend TTM	-	EV/Sales	1.38	EPS Y/Y TTM	-229.24%	Oper. Margin	-12.44%	ATR (14)	1.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.11	Sales Y/Y TTM	3.66%	Profit Margin	-7.02%	RSI (14)	37.04	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-125.03%	SMA20	-2.28%	Beta	1.20	Target Price	48.50
Payout	-	Debt/Eq	0.08	Sales Q/Q	0.81%	SMA50	-18.70%	Rel Volume	0.72	Prev Close	25.05
Employees	883	LT Debt/Eq	0.07	Earnings	Feb 26 AMC	SMA200	-11.05%	Avg Volume	403.06K	Price	24.84
IPO	Jul 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	69.06% 8.91%	Trades		Volume	288,524	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Mar-27-26 09:05AM	Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 (PR Newswire)
Mar-13-26 11:02AM	Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB (GlobeNewswire)
Mar-09-26 07:00AM	DecisionDx-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk (GlobeNewswire)
Mar-04-26 04:30PM	Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB (GlobeNewswire)
Mar-03-26 04:30PM	Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas (GlobeNewswire)
11:43AM	Loading…
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks) -5.34%
09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) -7.25%
12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
08:30AM	Castle Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:06AM	Loading…
12:06AM	Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Feb-26-26 06:00PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:48PM	Castle Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:56AM	Loading…
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -6.80%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 05:46PM	Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -6.92%
11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
09:35AM	Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.32%
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 (GlobeNewswire)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks) -10.22%
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Jan-30-26 08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -7.77%
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 12:00PM	Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice (Zacks)
Jan-11-26 04:00PM	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-02-26 10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
Dec-30-25 11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 10:17AM	Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus (Zacks)
09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-24-25 11:22AM	FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug (Zacks)
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
08:55AM	What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' (Zacks)
Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Option Exercise	2.39	550	1,314	22,029	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	3,622	92,546	3,058	Mar 30 06:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '26	Sale	25.55	550	14,053	21,479	Mar 30 06:29 PM
Derek Maetzold	Officer	Mar 26 '26	Proposed Sale	24.70	18,180	449,046		Mar 26 05:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 17 '26	Sale	25.93	18,650	483,594	22,129	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 18 '26	Sale	25.39	650	16,504	21,479	Mar 19 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 16 '26	Sale	25.97	17,575	456,408	40,779	Mar 17 04:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 13 '26	Sale	25.45	13,204	336,002	58,354	Mar 17 04:36 PM
Juvenal Tobin W	Chief Commercial Officer	Mar 12 '26	Sale	25.24	20,863	526,582	86,825	Mar 16 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Option Exercise	2.39	6,226	14,880	112,047	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 12 '26	Sale	25.28	23,179	585,942	71,558	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	17,310	451,947	94,737	Mar 13 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 11 '26	Sale	26.11	3,636	94,932	3,336	Mar 13 04:10 PM
Tobin Juvenal	Chief Commercial Officer	Mar 12 '26	Proposed Sale	25.32	20,863	528,251		Mar 12 04:38 PM
Derek Maetzold	Officer	Mar 11 '26	Proposed Sale	26.13	94,204	2,461,551		Mar 11 04:52 PM
Stokes Frank	Chief Financial Officer	Mar 05 '26	Sale	27.98	6,001	167,908	60,085	Mar 09 04:13 PM
Cole G Bradley	Director	Mar 05 '26	Option Exercise	3.38	4,748	16,048	26,712	Mar 09 04:12 PM
Cole G Bradley	Director	Mar 05 '26	Sale	28.47	7,403	210,727	19,309	Mar 09 04:12 PM
Stokes Frank	Chief Financial Officer	Mar 04 '26	Option Exercise	3.38	3,800	12,844	66,086	Mar 05 05:08 PM
Stokes Frank	Chief Financial Officer	Mar 03 '26	Sale	27.44	7,000	192,073	52,483	Mar 05 05:08 PM
FRANKLIN STOKES	Officer	Mar 05 '26	Proposed Sale	28.17	6,001	169,048		Mar 05 04:28 PM
GORDON B. COLE	Director	Mar 05 '26	Proposed Sale	28.47	7,403	210,743		Mar 05 04:04 PM
FRANKLIN STOKES	Officer	Mar 03 '26	Proposed Sale	27.99	7,000	195,930		Mar 03 04:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 03 '26	Sale	39.91	3,200	127,722	84,515	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Feb 04 '26	Sale	37.99	817	31,035	83,698	Feb 05 04:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 20 '26	Sale	40.01	4,017	160,732	87,715	Jan 22 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 05 '26	Sale	38.09	2,678	102,005	30,852	Jan 07 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '26	Sale	40.10	1,339	53,689	29,513	Jan 07 04:06 PM
Derek Maetzold	Officer	Jan 05 '26	Proposed Sale	39.00	12,051	469,989		Jan 05 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '25	Sale	40.35	830	33,490	33,530	Dec 29 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '25	Sale	40.04	509	20,380	34,360	Dec 19 04:06 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 17 '25	Sale	39.31	14,888	585,292	12,323	Dec 19 04:06 PM
Kristen M. Oelschlager	Officer	Dec 17 '25	Proposed Sale	39.05	14,888	581,376		Dec 17 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '25	Sale	38.78	19,525	757,099	47,690	Dec 17 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '25	Sale	38.55	12,821	494,301	34,869	Dec 17 04:20 PM
Derek Maetzold	Officer	Dec 15 '25	Proposed Sale	38.88	33,685	1,309,673		Dec 15 06:21 PM
Juvenal Tobin W	Chief Commercial Officer	Dec 11 '25	Sale	37.48	13,200	494,736	86,825	Dec 15 04:09 PM
Stokes Frank	Chief Financial Officer	Dec 11 '25	Sale	37.45	4,496	168,375	50,326	Dec 15 04:08 PM
TOBIN JUVENAL	Officer	Dec 11 '25	Proposed Sale	37.48	13,200	494,675		Dec 11 04:30 PM
FRANKLIN M. STOKES	Officer	Dec 11 '25	Proposed Sale	37.45	4,496	168,375		Dec 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '25	Sale	40.03	1,339	53,600	37,547	Dec 08 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 02 '25	Sale	39.23	2,678	105,058	38,886	Dec 04 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 26 '25	Sale	40.09	4,258	170,703	41,564	Dec 01 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 25 '25	Sale	40.05	5,115	204,851	45,822	Nov 26 02:58 PM
Derek Maetzold	Officer	Nov 25 '25	Proposed Sale	39.93	10,712	427,730		Nov 25 05:11 PM
TOBIN JUVENAL	Officer	Nov 24 '25	Proposed Sale	37.88	1,301	49,282		Nov 24 04:28 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Option Exercise	3.38	4,693	15,862	89,288	Nov 24 04:24 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Sale	35.58	4,693	166,977	84,595	Nov 24 04:24 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 18 '25	Sale	34.02	2,678	91,106	50,937	Nov 20 04:07 PM
Stokes Frank	Chief Financial Officer	Nov 11 '25	Sale	35.08	5,388	189,011	43,328	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 11 '25	Sale	35.39	500	17,695	84,027	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 12 '25	Sale	35.40	200	7,080	83,827	Nov 13 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Nov 11 '25	Sale	35.10	18,932	664,513	12,323	Nov 13 04:07 PM
Kristen M. Oelschlager	Officer	Nov 11 '25	Proposed Sale	34.74	18,932	657,698		Nov 12 09:32 AM
TOBIN JUVENAL	Officer	Nov 11 '25	Proposed Sale	34.74	5,393	187,353		Nov 12 07:03 AM
FRANKLIN STOKES	Officer	Nov 11 '25	Proposed Sale	34.74	5,388	187,179		Nov 12 06:58 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '25	Sale	30.44	6,695	203,782	56,293	Nov 06 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 05 '25	Sale	31.85	2,678	85,297	53,615	Nov 06 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 31 '25	Sale	25.04	12,678	317,457	27,569	Nov 04 08:56 PM
Derek Maetzold	Officer	Nov 04 '25	Proposed Sale	31.63	13,390	423,526		Nov 04 04:53 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 20 '25	Sale	22.44	1,339	30,047	62,988	Oct 23 09:30 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 02 '25	Sale	22.58	1,339	30,235	64,327	Oct 06 04:11 PM
Derek Maetzold	Officer	Oct 02 '25	Proposed Sale	22.23	4,017	89,298		Oct 02 05:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 17 '25	Sale	21.97	1,339	29,419	65,666	Sep 19 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 02 '25	Sale	23.93	1,339	32,042	67,005	Sep 04 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	22.02	12,677	279,135	141,116	Aug 29 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	21.69	18,007	390,572	153,793	Aug 29 04:04 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	18,007	384,449		Aug 27 06:15 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	25,355	541,329		Aug 27 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 15 '25	Sale	20.04	1,339	26,834	68,344	Aug 19 04:04 PM
Derek Maetzold	Officer	Aug 15 '25	Proposed Sale	20.09	4,017	80,702		Aug 15 05:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 13 '25	Sale	19.50	43,019	839,043	69,683	Aug 15 04:14 PM
Derek Maetzold	Officer	Aug 13 '25	Proposed Sale	19.41	43,019	834,999		Aug 13 05:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 08 '25	Option Exercise	0.00	66,991	0	136,674	Aug 12 04:32 PM
Stokes Frank	Chief Financial Officer	Aug 08 '25	Option Exercise	0.00	9,744	0	53,072	Aug 12 04:31 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	174,604	Aug 12 04:31 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	88,821	Aug 12 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	17,632	357,930	3,615	Jul 01 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	4,944	100,363	69,683	Jul 01 04:05 PM
Derek Maetzold	Officer	Jun 27 '25	Proposed Sale	20.35	16,932	344,566		Jun 27 06:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	4,408	94,851	4,275	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	1,236	26,596	74,627	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	3,647	73,739	4,440	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	1,023	20,684	75,863	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	761	15,243	4,577	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	213	4,266	76,886	Apr 10 04:07 PM
Derek Maetzold	Officer	Apr 08 '25	Proposed Sale	18.60	16,932	314,935		Apr 08 04:56 PM

Open in Screener

VCYT

Veracyte Inc

Apr 02 • 04:00PM ET

32.25

-0.15 -0.46 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: IJR VTI XBI VB FBT IWM ARKK VBK VXF ARKG

Index	RUT	P/E	39.27	EPS (ttm)	0.82	Insider Own	2.16%	Shs Outstand	79.36M	Perf Week	-1.68%
Market Cap	2.56B	Forward P/E	17.98	EPS next Y	1.79	Insider Trans	-13.56%	Shs Float	77.74M	Perf Month	-11.08%
Enterprise Value	2.19B	PEG	7.99	EPS next Q	0.33	Inst Own	108.80%	Short Float	6.92%	Perf Quarter	-23.40%
Income	66.35M	P/S	4.96	EPS this Y	-6.81%	Inst Trans	-3.11%	Short Ratio	5.81	Perf Half Y	-10.94%
Sales	517.14M	P/B	1.95	EPS next Y	8.15%	ROA	4.79%	Short Interest	5.38M	Perf YTD	-23.40%
Book/sh	16.50	P/C	6.21	EPS next 5Y	2.25%	ROE	5.34%	52W High	50.71 -36.40%	Perf Year	7.04%
Cash/sh	5.20	P/FCF	20.24	EPS past 3/5Y	- -	ROIC	4.93%	52W Low	22.61 42.64%	Perf 3Y	44.62%
Dividend Est.	-	EV/EBITDA	25.54	Sales past 3/5Y	20.37% 34.50%	Gross Margin	68.81%	Volatility	5.98% 4.30%	Perf 5Y	-38.83%
Dividend TTM	-	EV/Sales	4.23	EPS Y/Y TTM	168.91%	Oper. Margin	12.44%	ATR (14)	1.57	Perf 10Y	503.93%
Dividend Ex-Date	-	Quick Ratio	7.81	Sales Y/Y TTM	16.01%	Profit Margin	12.83%	RSI (14)	44.69	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	8.15	EPS Q/Q	690.00%	SMA20	-0.65%	Beta	2.02	Target Price	48.09
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	18.55%	SMA50	-8.58%	Rel Volume	0.76	Prev Close	32.40
Employees	755	LT Debt/Eq	0.03	Earnings	Feb 25 AMC	SMA200	-7.59%	Avg Volume	925.18K	Price	32.25
IPO	Oct 30, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.52% 3.84%	Trades		Volume	702,900	Change	-0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Underweight	$48
Oct-20-25	Initiated	Canaccord Genuity	Hold	$40
Mar-20-25	Initiated	Craig Hallum	Buy	$45
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Mar-16-26 04:15PM	Veracyte Names Kevin Haas as Chief Development and Technology Officer (Business Wire)
Mar-02-26 12:59PM	OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis (Zacks)
Feb-27-26 12:37PM	GEHC & UCSF Form 10-Year Alliance to Advance Imaging & Care Delivery (Zacks) -5.57%
Feb-26-26 11:46AM	GEHC Unveils AI LOGIQ Ultrasound Systems to Boost Imaging & Workflow (Zacks) +8.48%
11:22AM	Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises (Zacks)
08:30AM	Loading…
08:30AM	Veracyte, Inc. Q4 2025 Earnings Call Summary (Moby)
04:32AM	Veracyte Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Veracyte Inc (VCYT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-25-26 08:05PM	Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:37PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
01:55PM	Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand (Zacks)
01:55PM	FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand (Zacks)
11:57AM	Stryker Launches Synchfix EVT for Flexible Syndesmotic Fixation (Zacks)
Feb-24-26 12:40PM	BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy (Zacks)
09:40AM	Loading…
09:40AM	AxoGen (AXGN) Q4 Earnings Miss Estimates (Zacks)
09:00AM	Veracyte to Highlight Extensive Decipher Data at 2026 ASCO GU Symposium (Business Wire)
Feb-23-26 12:42PM	ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation (Zacks)
09:45AM	Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
09:25AM	Does Veracyte (VCYT) Offer Both Strength and Opportunity? (Insider Monkey)
Feb-20-26 12:22PM	GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio (Zacks)
11:44AM	ITGR Shares Down Despite Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-19-26 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
11:05AM	Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal (Zacks)
Feb-18-26 01:09PM	GEHC Expands BARDA Collaboration With $35M Boost for AI Ultrasound (Zacks)
10:53AM	Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook (Zacks)
10:39AM	Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? (Zacks)
Feb-17-26 10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
09:19AM	Henry Schein Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-16-26 08:59AM	NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro (Zacks)
08:54AM	Loading…
08:54AM	Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings (Zacks)
Feb-15-26 08:42AM	UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue (Insider Monkey)
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Feb-11-26 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks)
Feb-10-26 12:20PM	GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency (Zacks)
11:22AM	Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth? (Zacks)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks)
10:40AM	GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration (Zacks)
08:02AM	Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance (Zacks)
Feb-06-26 09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 05:40PM	Mettler-Toledo (MTD) Q4 Earnings and Revenues Beat Estimates (Zacks)
12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
09:35AM	Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-04-26 05:15PM	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
12:51PM	Here's Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
10:23AM	Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:47AM	Will Pharmacy and Consumer Wellness Segment Lead CVS' Q4 Earnings? (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
11:38AM	Zimmer Biomet to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
09:13AM	Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings? (Zacks)
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
09:55AM	Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:28AM	HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
08:02AM	Here's How Align Technology Is Placed Ahead of Q4 Earnings (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
07:46AM	PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results (Zacks)
07:43AM	Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings (Zacks)
07:27AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings? (Zacks)
07:26AM	STERIS' Q3 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-27-26 12:19PM	Here's Why You Should Add Merit Medical Stock to Your Portfolio Now (Zacks)
12:07PM	ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures (Zacks)
07:54AM	Resmed's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
07:53AM	CLPT Gets EU MDR Certification for ClearPoint Navigation Software (Zacks)
Jan-26-26 12:10PM	Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-23-26 01:50PM	WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
07:17AM	Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? (Zacks)
Jan-22-26 11:08AM	Here's Why You Should Retain Integer Holdings Stock in Your Portfolio (Zacks)
09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
03:25AM	Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating (Insider Monkey)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
Jan-19-26 12:40PM	Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
07:37AM	Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings? (Zacks)
Jan-14-26 01:11PM	Option Care Health Stock Earns Healthy RS Rating Upgrade (Investor's Business Daily)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-11-26 04:30PM	Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Business Wire)
Jan-08-26 09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks (Zacks)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 11:48PM	Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT) (Insider Monkey)
10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
05:48AM	Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical (Zacks)
Dec-29-25 04:30PM	Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:23AM	3 Medical Instrument Stocks to Counter Industry Woes Using GenAI (Zacks)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chambers Rebecca	Chief Financial Officer	Mar 04 '26	Sale	36.14	18,341	662,869	131,196	Mar 06 04:33 PM
Stapley Marc	Chief Executive Officer	Mar 04 '26	Sale	35.97	45,523	1,637,594	357,554	Mar 06 04:32 PM
Leite John	Chief Commercial Officer-CLIA	Mar 04 '26	Sale	35.19	5,260	185,083	107,580	Mar 06 04:32 PM
McGuire Annie	SVP, General Counsel	Mar 04 '26	Sale	35.55	6,658	236,725	94,706	Mar 06 04:32 PM
ANN MCGUIRE	Officer	Mar 04 '26	Proposed Sale	35.08	6,658	233,563		Mar 04 04:42 PM
John Leite	Officer	Mar 04 '26	Proposed Sale	35.08	5,260	184,521		Mar 04 04:41 PM
REBECCA CHAMBERS	Officer	Mar 04 '26	Proposed Sale	35.08	18,341	643,402		Mar 04 04:40 PM
MARC STAPLEY	Director	Mar 04 '26	Proposed Sale	35.08	45,523	1,596,947		Mar 04 04:37 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Mar 02 '26	Sale	36.16	13,425	485,429	117,346	Mar 04 04:16 PM
PHILLIP FEBBO	Officer	Mar 02 '26	Proposed Sale	36.59	13,425	491,221		Mar 02 04:38 PM
McGuire Annie	SVP, General Counsel	Dec 16 '25	Sale	43.13	10,739	463,204	67,760	Dec 17 04:35 PM
ANN MCGUIRE	Officer	Dec 16 '25	Proposed Sale	43.53	10,739	467,469		Dec 16 04:30 PM
EASTHAM KARIN	Director	Dec 05 '25	Option Exercise	7.77	20,000	155,400	33,554	Dec 08 04:34 PM
EASTHAM KARIN	Director	Dec 05 '25	Sale	45.45	20,000	908,923	13,554	Dec 08 04:34 PM
KARIN EASTHAM	Director	Dec 05 '25	Proposed Sale	47.41	20,000	948,200		Dec 05 04:26 PM
McGuire Annie	SVP, General Counsel	Dec 04 '25	Sale	47.30	1,422	67,261	78,499	Dec 04 07:44 PM
Chambers Rebecca	Chief Financial Officer	Dec 04 '25	Sale	46.84	13,278	621,955	109,496	Dec 04 07:44 PM
Stapley Marc	Chief Executive Officer	Dec 04 '25	Sale	47.09	7,668	361,076	318,603	Dec 04 07:44 PM
Leite John	Chief Commercial Officer-CLIA	Dec 04 '25	Sale	47.51	1,278	60,718	82,113	Dec 04 07:43 PM
ANN MCGUIRE	Officer	Dec 04 '25	Proposed Sale	47.75	1,422	67,900		Dec 04 04:39 PM
REBECCA CHAMBERS	Officer	Dec 04 '25	Proposed Sale	47.75	13,278	634,024		Dec 04 04:39 PM
MARC STAPLEY	Director	Dec 04 '25	Proposed Sale	47.75	7,668	366,147		Dec 04 04:38 PM
Leite John	Chief Commercial Officer-CLIA	Nov 25 '25	Sale	50.00	2,808	140,400	86,291	Nov 26 04:27 PM
JONES EVAN/ FA	Director	Nov 25 '25	Sale	50.25	1,106	55,576	29,362	Nov 26 04:27 PM
Evan Jones	Director	Nov 25 '25	Proposed Sale	49.38	5,000	246,900		Nov 25 07:25 PM
John Leite	Officer	Nov 25 '25	Proposed Sale	46.70	4,086	190,816		Nov 25 04:28 PM
Holstein Jens	Director	Nov 20 '25	Sale	42.36	10,000	423,563	27,199	Nov 21 04:19 PM
JENS HOLSTEIN	Director	Nov 20 '25	Proposed Sale	42.36	10,000	423,563		Nov 20 04:03 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 07 '25	Sale	40.21	5,818	233,929	43,847	Nov 12 04:25 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 10 '25	Sale	42.33	5,102	215,978	38,745	Nov 12 04:25 PM
McGuire Annie	SVP, General Counsel	Nov 05 '25	Sale	40.00	6,466	258,640	82,973	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Option Exercise	6.94	30,000	208,200	73,664	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Sale	45.06	43,196	1,946,288	30,468	Nov 07 04:10 PM
EASTHAM KARIN	Director	Nov 05 '25	Sale	40.02	9,674	387,191	13,554	Nov 07 04:10 PM
Chambers Rebecca	Chief Financial Officer	Nov 05 '25	Sale	41.00	7,000	287,000	126,158	Nov 07 04:10 PM
Evan Jones	Director	Nov 05 '25	Proposed Sale	46.04	43,196	1,988,744		Nov 05 09:47 PM
KARIN EASTHAM	Director	Nov 05 '25	Proposed Sale	36.12	9,674	349,425		Nov 05 04:18 PM
ANN MCGUIRE	Officer	Nov 05 '25	Proposed Sale	36.12	6,466	233,552		Nov 05 04:18 PM
REBECCA CHAMBERS	Officer	Nov 05 '25	Proposed Sale	36.12	7,000	252,840		Nov 05 04:17 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Oct 06 '25	Sale	36.02	8,349	300,709	92,441	Oct 07 04:27 PM
PHILLIP FEBBO	Officer	Oct 06 '25	Proposed Sale	36.00	8,349	300,564		Oct 06 04:19 PM
Leite John	Chief Commercial Officer-CLIA	Oct 01 '25	Sale	35.00	2,539	88,865	89,099	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Option Exercise	7.94	10,000	79,400	83,919	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Sale	35.08	21,473	753,204	62,446	Oct 03 04:16 PM
McGuire Annie	SVP, General Counsel	Oct 01 '25	Sale	35.00	2,160	75,608	89,439	Oct 03 04:16 PM
ROBERT S EPSTEIN	Director	Oct 01 '25	Proposed Sale	34.33	21,473	737,168		Oct 01 04:27 PM
John Leite	Officer	Oct 01 '25	Proposed Sale	34.33	2,539	87,164		Oct 01 04:27 PM
ANN MCGUIRE	Officer	Oct 01 '25	Proposed Sale	34.33	2,160	74,153		Oct 01 04:26 PM
McGuire Annie	SVP, General Counsel	Sep 19 '25	Sale	33.69	2,283	76,920	91,599	Sep 23 04:18 PM
ANN MCGUIRE	Officer	Sep 19 '25	Proposed Sale	33.23	2,283	75,864		Sep 19 04:25 PM
Stapley Marc	Chief Executive Officer	Sep 04 '25	Sale	30.41	7,667	233,133	334,185	Sep 08 04:33 PM
MARC STAPLEY	Director	Sep 04 '25	Proposed Sale	30.62	7,667	234,764		Sep 04 04:26 PM
EASTHAM KARIN	Director	Jun 13 '25	Sale	26.66	4,590	122,388	13,907	Jun 17 04:21 PM
Bhanji Muna	Director	Jun 13 '25	Sale	26.67	4,589	122,367	29,989	Jun 17 04:21 PM
KARIN EASTHAM	Director	Jun 13 '25	Proposed Sale	26.69	4,590	122,507		Jun 13 04:46 PM
MUNA BHANJI	Director	Jun 13 '25	Proposed Sale	26.69	4,589	122,480		Jun 13 04:45 PM
Leite John	Chief Commercial Officer-CLIA	Jun 04 '25	Sale	27.20	2,809	76,410	94,540	Jun 06 04:19 PM
JOHN LEITE	Officer	Jun 04 '25	Proposed Sale	26.50	2,809	74,438		Jun 04 04:21 PM

Open in Screener

BDSX

Biodesix Inc

Apr 02 • 04:00PM ET

15.07

+0.31 2.10 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN BEAM CDNA FLGT GH EXAS QDEL TWST CRSP PACB

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-4.73	Insider Own	60.82%	Shs Outstand	8.25M	Perf Week	3.22%
Market Cap	148.57M	Forward P/E	-	EPS next Y	-1.95	Insider Trans	2.94%	Shs Float	3.86M	Perf Month	-1.50%
Enterprise Value	202.33M	PEG	-	EPS next Q	-1.08	Inst Own	17.54%	Short Float	4.64%	Perf Quarter	121.62%
Income	-35.27M	P/S	1.68	EPS this Y	34.19%	Inst Trans	14.28%	Short Ratio	0.12	Perf Half Y	96.48%
Sales	88.50M	P/B	-	EPS next Y	36.67%	ROA	-37.35%	Short Interest	0.18M	Perf YTD	121.62%
Book/sh	-0.30	P/C	7.78	EPS next 5Y	34.21%	ROE	-383.09%	52W High	20.21 -25.43%	Perf Year	20.04%
Cash/sh	1.94	P/FCF	-	EPS past 3/5Y	46.84% 27.68%	ROIC	-51.09%	52W Low	3.44 338.59%	Perf 3Y	-59.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	32.31% 14.20%	Gross Margin	81.11%	Volatility	7.68% 9.70%	Perf 5Y	-96.28%
Dividend TTM	-	EV/Sales	2.29	EPS Y/Y TTM	32.65%	Oper. Margin	-31.37%	ATR (14)	1.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.79	Sales Y/Y TTM	24.08%	Profit Margin	-39.85%	RSI (14)	50.75	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.86	EPS Q/Q	56.16%	SMA20	-7.67%	Beta	0.64	Target Price	30.00
Payout	-	Debt/Eq	-	Sales Q/Q	40.76%	SMA50	9.60%	Rel Volume	0.03	Prev Close	14.76
Employees	334	LT Debt/Eq	-	Earnings	Feb 26 AMC	SMA200	67.59%	Avg Volume	1.45M	Price	15.07
IPO	Oct 28, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	43.04% 11.77%	Trades		Volume	40,536	Change	2.10%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-26	Upgrade	William Blair	Mkt Perform → Outperform
May-14-25	Downgrade	William Blair	Outperform → Mkt Perform
Sep-16-24	Initiated	Scotiabank	Sector Outperform
Jul-26-24	Initiated	Craig Hallum	Buy	$3
May-13-24	Initiated	TD Cowen	Buy	$2.80
May-03-24	Initiated	Lake Street	Buy	$3
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21 → $11
Nov-23-20	Initiated	William Blair	Outperform
Nov-23-20	Initiated	Morgan Stanley	Overweight	$20
Nov-23-20	Initiated	Canaccord Genuity	Buy	$26
Nov-23-20	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Mar-20-26 08:06AM	Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis (GlobeNewswire) -8.74%
Mar-06-26 07:38AM	Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference (MarketBeat) +18.41%
Mar-03-26 09:55AM	Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet (Zacks)
09:40AM	Are Medical Stocks Lagging Biodesix (BDSX) This Year? (Zacks)
Feb-27-26 12:04AM	Biodesix Inc (BDSX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +7.81%
05:48PM	Loading…
Feb-26-26 05:48PM	Biodesix Q4 Earnings Call Highlights (MarketBeat) +9.98%
05:15PM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights (GlobeNewswire)
Feb-25-26 07:42AM	Earnings To Watch: Biodesix Inc (BDSX) Reports Q4 2025 Result (GuruFocus.com)
Feb-24-26 06:00AM	Biodesix to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-26 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-31-26 08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-12-26 06:00AM	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) (GlobeNewswire) +47.99%
Dec-24-25 01:48PM	SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio (Zacks)
Dec-19-25 11:05AM	Cencora to Acquire OneOncology to Expand Community Oncology Solutions (Zacks) -5.77%
09:55AM	Loading…
Dec-03-25 09:55AM	Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade (Zacks)
08:22AM	Biodesix to Present New Data at Two Major Upcoming Scientific Meetings (GlobeNewswire)
Nov-04-25 12:01AM	Biodesix Inc (BDSX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Costs (GuruFocus.com) +19.87%
Nov-03-25 05:30PM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.17%
04:01PM	Biodesix Announces Third Quarter 2025 Results and Highlights (GlobeNewswire)
Oct-31-25 09:35AM	What To Expect From Biodesix Inc (BDSX) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 06:17AM	Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting (GlobeNewswire)
Oct-29-25 05:45PM	Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-27-25 07:10AM	Revvity (RVTY) Surpasses Q3 Earnings Estimates (Zacks)
Oct-22-25 06:17AM	Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays (GlobeNewswire) -12.15%
Oct-20-25 06:00AM	Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-15-25 06:09AM	Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting (GlobeNewswire)
Oct-06-25 10:13AM	Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit (GlobeNewswire)
Sep-11-25 08:00AM	Biodesix Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -20.82%
Sep-05-25 06:00AM	Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference (GlobeNewswire)
10:30AM	Loading…
Sep-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.05%
Aug-19-25 09:47AM	Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics (GlobeNewswire)
Aug-07-25 05:20PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.62% -10.40%
04:06PM	Biodesix Announces Second Quarter 2025 Results and Highlights (GlobeNewswire)
Aug-05-25 06:00AM	Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +10.10%
Aug-01-25 07:15AM	Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates (Zacks)
Jul-25-25 12:22PM	Biodesix, APAPP Partner to Launch First CME-Accredited Education Program for Lung Cancer Biomarkers (Insider Monkey) +6.80%
12:22PM	Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy (Insider Monkey)
Jul-24-25 06:00AM	Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jun-10-25 06:17AM	Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs (GlobeNewswire) +13.91%
May-22-25 05:03PM	Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.92%
May-21-25 06:00AM	Biodesix to Participate in Upcoming Investor Conferences (GlobeNewswire) +45.90%
May-15-25 06:00AM	Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS (GlobeNewswire)
May-14-25 04:01PM	Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award (GlobeNewswire) -38.74%
03:16AM	Biodesix Inc (BDSX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Sales Team ... (GuruFocus.com)
May-13-25 05:15PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2025 Results and Highlights (GlobeNewswire)
May-12-25 09:50AM	Biodesix Inc (BDSX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:25AM	Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:30PM	DocGo Inc. (DCGO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.91% +6.84%
Apr-30-25 07:45AM	GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
Apr-29-25 06:00AM	Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire) -6.51%
Apr-28-25 07:15AM	Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates (Zacks) +6.25%
Apr-25-25 07:15AM	Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates (Zacks) -5.64%
Apr-23-25 06:00AM	Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types (GlobeNewswire)
Mar-06-25 12:00PM	Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-04-25 05:20AM	Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey)
02:03AM	Biodesix Inc (BDSX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-03-25 04:01PM	Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results (GlobeNewswire) -10.09%
Feb-28-25 07:15AM	Biodesix Inc (BDSX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-25 06:00AM	Biodesix to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (GlobeNewswire)
Jan-10-25 06:00AM	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) (GlobeNewswire) -14.19%
Jan-07-25 06:00AM	Biodesix Announces Publication of a New Nodify CDT Clinical Validation Study (GlobeNewswire)
Nov-20-24 09:35AM	Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-02-24 03:01AM	Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com)
Nov-01-24 07:15AM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -23.53%
06:00AM	Biodesix Announces Third Quarter 2024 Results and Highlights (GlobeNewswire)
Oct-31-24 09:06AM	What To Expect From Biodesix Inc (BDSX) Q3 2024 Earnings (GuruFocus.com)
Oct-29-24 06:00AM	Biodesix to Participate in Three Investor Conferences in November (GlobeNewswire)
Oct-18-24 06:00AM	Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 (Business Wire)
Oct-07-24 06:00AM	Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study (Business Wire)
Sep-05-24 06:00AM	Biodesix to Present at Two Investor Conferences in September (Business Wire)
Aug-08-24 10:23AM	Q2 2024 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 06:05PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2024 Results and Highlights (Business Wire)
Aug-06-24 06:00AM	Biodesix to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
Jul-24-24 06:00AM	Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jun-18-24 08:13AM	Biodesix Named to Inc. Magazine's 2024 "Best Workplaces" (Business Wire)
May-28-24 06:00AM	Biodesix to Participate in Two Investor Conferences in June (Business Wire)
May-21-24 06:00AM	Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting (Business Wire)
May-10-24 05:59PM	Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:55PM	Biodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance (GuruFocus.com)
May-09-24 03:46AM	Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-24 09:00PM	BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management (Business Wire)
May-07-24 06:00AM	Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference (Business Wire)
Apr-24-24 06:00AM	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-09-24 05:00PM	Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting (Business Wire) -9.93%
Apr-05-24 07:17AM	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement (Business Wire) -7.28%
Mar-25-24 06:00AM	Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center (Business Wire)
Mar-04-24 09:04AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 10:40PM	Q4 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
06:31AM	Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin (GuruFocus.com)
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights (Business Wire)
Feb-26-24 06:00AM	Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-16-24 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 (Business Wire) -5.73%
Feb-13-24 03:00AM	Biodesix Inc CEO Scott Hutton Sells 64,390 Shares (GuruFocus.com)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pestano Gary Anthony	Chief Development Officer	Feb 23 '26	Sale	12.78	556	7,103	10,359	Feb 23 08:22 PM
O'Kane Kieran	Chief Commercial Officer	Feb 23 '26	Sale	12.78	535	6,835	9,819	Feb 23 08:22 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 23 '26	Sale	12.78	535	6,835	16,231	Feb 23 08:22 PM
Vazquez Chris	Chief Accounting Officer	Feb 23 '26	Sale	12.78	211	2,696	1,586	Feb 23 08:22 PM
Hutton Scott	President & CEO	Feb 23 '26	Sale	12.78	1,490	19,036	48,767	Feb 23 08:22 PM
Hutton Scott	Officer	Feb 23 '26	Proposed Sale	12.77	1,490	19,027		Feb 23 08:22 PM
O'Kane Kieran	Chief Commercial Officer	Feb 10 '26	Sale	10.08	584	5,889	8,885	Feb 11 06:03 PM
Vazquez Chris	Chief Accounting Officer	Feb 10 '26	Sale	10.08	101	1,018	1,234	Feb 11 06:03 PM
Hutton Scott	President & CEO	Feb 10 '26	Sale	10.08	3,559	35,889	45,413	Feb 11 06:03 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 10 '26	Sale	10.08	941	9,489	15,297	Feb 11 06:03 PM
Pestano Gary Anthony	Chief Development Officer	Feb 10 '26	Sale	10.08	540	5,445	9,387	Feb 11 06:03 PM
SCHULER JACK W	Emeritus Director	Jan 23 '26	Buy	11.81	80,000	944,672	1,543,210	Jan 27 09:29 AM
SCHULER JACK W	Emeritus Director	Jan 26 '26	Buy	11.80	20,000	236,064	1,563,210	Jan 27 09:29 AM
SCHULER JACK W	Emeritus Director	Jan 22 '26	Buy	10.96	82,465	903,561	1,463,210	Jan 26 09:28 AM
Vazquez Chris	Chief Accounting Officer	Jan 16 '26	Sale	8.15	83	676	1,072	Jan 20 04:22 PM
Pestano Gary Anthony	Chief Development Officer	Jan 16 '26	Sale	8.15	298	2,428	8,446	Jan 20 04:21 PM
O'Kane Kieran	Chief Commercial Officer	Jan 16 '26	Sale	8.15	298	2,428	7,869	Jan 20 04:21 PM
Hutton Scott	President & CEO	Jan 16 '26	Sale	8.15	970	7,905	38,974	Jan 20 04:21 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Jan 16 '26	Sale	8.15	298	2,428	13,654	Jan 20 04:21 PM
Vazquez Chris	Chief Accounting Officer	Nov 10 '25	Sale	7.62	13	99	936	Nov 13 04:54 PM
Pestano Gary Anthony	Chief Development Officer	Nov 10 '25	Sale	7.62	23	175	7,939	Nov 13 04:54 PM
O'Kane Kieran	Chief Commercial Officer	Nov 10 '25	Sale	7.62	25	190	7,362	Nov 13 04:53 PM
Hutton Scott	President & CEO	Nov 10 '25	Sale	7.62	189	1,440	37,311	Nov 13 04:53 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 10 '25	Sale	7.62	50	381	13,147	Nov 13 04:53 PM
SCHULER JACK W	Director	Sep 19 '25	Buy	7.04	142,045	999,997	1,380,745	Sep 23 09:29 AM
SCHULER JACK W	Director	Sep 17 '25	Buy	6.04	15,317	92,571	1,235,644	Sep 19 10:31 AM
SCHULER JACK W	Director	Sep 18 '25	Buy	6.17	3,056	18,854	1,238,700	Sep 19 10:31 AM
SCHULER JACK W	Director	Aug 29 '25	Buy	0.43	3,488,372	1,500,000	24,406,546	Sep 03 04:42 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 13 '25	Sale	0.42	988	411	250,794	Aug 14 05:25 PM
Hutton Scott	President & CEO	Aug 13 '25	Sale	0.42	3,772	1,570	728,824	Aug 14 05:25 PM
O'Kane Kieran	Chief Commercial Officer	Aug 13 '25	Sale	0.42	476	198	140,065	Aug 14 05:24 PM
Pestano Gary Anthony	Chief Development Officer	Aug 13 '25	Sale	0.42	442	184	157,878	Aug 14 05:24 PM
Vazquez Chris	Chief Accounting Officer	Aug 13 '25	Sale	0.42	228	95	18,375	Aug 14 05:24 PM
SCHULER JACK W	Director	May 16 '25	Buy	0.27	4,000,000	1,070,000	20,194,935	May 20 04:11 PM
SCHULER JACK W	Director	May 19 '25	Buy	0.34	723,239	246,624	20,918,174	May 20 04:11 PM
Vazquez Chris	Chief Accounting Officer	May 12 '25	Sale	0.36	112	40	18,113	May 13 06:36 PM
Vazquez Chris	Chief Accounting Officer	May 13 '25	Sale	0.35	112	40	18,001	May 13 06:36 PM
Pestano Gary Anthony	Chief Development Officer	May 12 '25	Sale	0.36	223	80	157,163	May 13 06:36 PM
Pestano Gary Anthony	Chief Development Officer	May 13 '25	Sale	0.35	222	78	156,941	May 13 06:36 PM
O'Kane Kieran	Chief Commercial Officer	May 12 '25	Sale	0.36	239	86	139,290	May 13 06:35 PM
O'Kane Kieran	Chief Commercial Officer	May 13 '25	Sale	0.35	238	84	139,052	May 13 06:35 PM
Hutton Scott	President & CEO	May 12 '25	Sale	0.36	1,888	679	722,271	May 13 06:35 PM
Hutton Scott	President & CEO	May 13 '25	Sale	0.35	1,887	666	720,384	May 13 06:35 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 12 '25	Sale	0.36	496	178	249,121	May 13 06:35 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 13 '25	Sale	0.35	496	175	248,625	May 13 06:35 PM

Open in Screener

LH

Labcorp Holdings Inc

Apr 02 • 04:00PM ET

273.72

+0.98 0.36 %

Healthcare • Diagnostics & Research • USA • NYSE

LH Labcorp Holdings Inc daily Stock Chart

Peers: DGX NEO OPK ICLR QDEL AVTR

| Held by: VTI VOO VO IVV SPY VTV RSP XLV VOE IWR

Index	S&P 500	P/E	26.17	EPS (ttm)	10.46	Insider Own	0.36%	Shs Outstand	82.20M	Perf Week	1.99%
Market Cap	22.55B	Forward P/E	14.15	EPS next Y	19.34	Insider Trans	-9.79%	Shs Float	82.10M	Perf Month	-2.54%
Enterprise Value	28.57B	PEG	1.65	EPS next Q	4.12	Inst Own	99.30%	Short Float	3.64%	Perf Quarter	9.10%
Income	876.50M	P/S	1.62	EPS this Y	8.67%	Inst Trans	1.77%	Short Ratio	4.26	Perf Half Y	-1.91%
Sales	13.95B	P/B	2.61	EPS next Y	8.28%	ROA	4.77%	Short Interest	2.99M	Perf YTD	9.10%
Book/sh	104.86	P/C	42.37	EPS next 5Y	8.60%	ROE	10.51%	52W High	293.72 -6.81%	Perf Year	15.80%
Cash/sh	6.46	P/FCF	18.70	EPS past 3/5Y	-9.18% -8.01%	ROIC	6.07%	52W Low	209.38 30.73%	Perf 3Y	38.88%
Dividend Est.	2.94 (1.08%)	EV/EBITDA	13.00	Sales past 3/5Y	5.55% -0.04%	Gross Margin	26.75%	Volatility	2.44% 2.36%	Perf 5Y	26.09%
Dividend TTM	2.88 (1.05%)	EV/Sales	2.05	EPS Y/Y TTM	18.61%	Oper. Margin	10.87%	ATR (14)	6.50	Perf 10Y	169.04%
Dividend Ex-Date	Feb 27, 2026	Quick Ratio	1.23	Sales Y/Y TTM	7.25%	Profit Margin	6.28%	RSI (14)	54.95	Recom	1.64
Dividend Gr. 3/5Y	10.06% -	Current Ratio	1.42	EPS Q/Q	16.24%	SMA20	2.41%	Beta	1.02	Target Price	309.88
Payout	27.54%	Debt/Eq	0.76	Sales Q/Q	5.60%	SMA50	-0.04%	Rel Volume	0.67	Prev Close	272.74
Employees	71000	LT Debt/Eq	0.68	Earnings	Feb 17 BMO	SMA200	2.22%	Avg Volume	701.79K	Price	273.72
IPO	Jul 07, 1988	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.13% -1.20%	Trades		Volume	467,231	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Downgrade	HSBC Securities	Buy → Hold	$260
Apr-02-25	Initiated	Redburn Atlantic	Buy	$276
Mar-04-25	Upgrade	Citigroup	Neutral → Buy	$250 → $300
Jan-07-25	Upgrade	Evercore ISI	In-line → Outperform	$260 → $265
Dec-10-24	Resumed	Jefferies	Buy	$265 → $275
Oct-30-24	Upgrade	HSBC Securities	Hold → Buy
Oct-01-24	Initiated	Piper Sandler	Neutral	$235
Mar-25-24	Upgrade	Argus	Hold → Buy	$250
Feb-26-24	Initiated	Leerink Partners	Outperform	$260
Feb-09-24	Initiated	Evercore ISI	In-line	$240
Jan-03-24	Initiated	Barclays	Equal Weight	$222
Sep-06-23	Initiated	HSBC Securities	Hold	$210
Dec-12-22	Downgrade	Citigroup	Buy → Neutral	$275 → $250
Sep-19-22	Downgrade	Argus	Buy → Hold
Aug-22-22	Resumed	Morgan Stanley	Overweight	$300
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$330 → $294
Jan-11-21	Upgrade	Argus	Hold → Buy	$245
Jan-11-21	Downgrade	Wolfe Research	Peer Perform → Underperform
Jan-08-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy	$194 → $220

Show Previous Ratings

Mar-31-26 04:15PM	Labcorp to Announce First Quarter Financial Results on April 30, 2026 (PR Newswire)
Mar-23-26 06:00AM	Labcorp closes purchase of New York pathology reference lab assets (MedTech Dive)
Mar-18-26 09:15AM	Illumina and Labcorp expand collaboration to broaden access to precision oncology testing (PR Newswire)
Mar-09-26 08:25AM	Q4 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Mar-06-26 09:40AM	Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
07:00AM	Loading…
07:00AM	Middleby Appoints Glenn Eisenberg To Board of Directors (Business Wire)
Mar-04-26 08:14AM	Is This the Right Time to Hold Labcorp Stock in Your Portfolio? (Zacks)
Feb-27-26 12:44PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
08:30AM	OPKO Health, Inc. Q4 2025 Earnings Call Summary (Moby)
01:12AM	OPKO Health Q4 Earnings Call Highlights (MarketBeat)
Feb-24-26 11:31PM	Labcorp expands PathAI pact to roll out digital pathology platform in US (MedTech Dive)
12:33AM	The 5 Most Interesting Analyst Questions From Labcorp's Q4 Earnings Call (StockStory)
Feb-23-26 07:00AM	Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide (PR Newswire)
Feb-19-26 09:50AM	Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term (Zacks)
07:21AM	Labcorp Holdings Stock: Is Wall Street Bullish or Bearish? (Barchart)
02:34PM	Loading…
Feb-18-26 02:34PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research)
09:40AM	Here's Why Labcorp Holdings (LH) is a Strong Value Stock (Zacks)
12:32AM	LH Q4 Deep Dive: Specialty Testing and Hospital Partnerships Offset Volume Challenges (StockStory)
Feb-17-26 08:06PM	Labcorp Holdings Inc. Q4 2025 Earnings Call Summary (Moby)
04:00PM	Labcorp Holdings Inc (LH) Q4 2025 Earnings Call Highlights: Strong Revenue and EPS Growth Amid ... (GuruFocus.com)
02:00PM	Why Labcorp (LH) Shares Are Trading Lower Today (StockStory)
01:46PM	Labcorp Q4 Earnings Call Highlights (MarketBeat)
11:11AM	Pre-Markets in Red to Start Holiday Shortened Week (Zacks)
10:35AM	Pre-Markets Begins Shorter Week Slowly (Zacks)
10:07AM	Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market (Zacks)
09:30AM	Labcorp (LH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:00AM	Labcorp Holdings (LH) Q4 Earnings Surpass Estimates (Zacks)
07:09AM	Labcorp: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Labcorp (NYSE:LH) Misses Q4 CY2025 Sales Expectations (StockStory)
06:50AM	Labcorp Announces 2025 Fourth Quarter and Full Year Results (PR Newswire)
10:07PM	Loading…
Feb-15-26 10:07PM	Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-13-26 08:29PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Feb-11-26 12:10PM	Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:15AM	Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
07:00AM	Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care (PR Newswire)
Feb-10-26 09:20PM	Labcorp closes takeover of Empire City assets to fuel New York expansion (MedTech Dive)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 01:54PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research)
08:30AM	Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors (PR Newswire)
Feb-05-26 07:38PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Feb-03-26 08:10AM	Investor Concerns Impacted Labcorp (LH) in Q4 (Insider Monkey)
Jan-26-26 09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-21-26 08:30AM	Sorry, 'Dr. Google.' ChatGPT and Claude are now getting into the business of providing health advice. (MarketWatch)
Jan-15-26 04:34PM	These charts show the stock market giving investors a lot to like - for now - as the S&P 500 nears 7,000 (MarketWatch)
04:15PM	Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026 (PR Newswire)
Jan-14-26 06:50AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Jan-13-26 07:00AM	Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk (PR Newswire)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
08:09AM	Labcorps Quarterly Earnings Preview: What You Need to Know (Barchart)
06:03AM	NAMSA acquires Labcorps medical device testing assets (Medical Device Network)
Jan-08-26 09:00AM	Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs (Business Wire)
08:30AM	NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp (PR Newswire)
Jan-06-26 08:12AM	Should Labcorp Stock Stay in Your Portfolio Right Now? (Zacks)
Dec-30-25 04:15PM	Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 09:40AM	Here's Why Labcorp Holdings (LH) is a Strong Value Stock (Zacks)
07:58AM	HOLX vs. LH: Which MedTech Stock Is the Stronger Investment Now? (Zacks)
Dec-18-25 09:55AM	Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth? (Zacks)
Dec-16-25 05:24AM	Is Charles River Laboratories Stock Underperforming the Dow? (Barchart)
Dec-15-25 09:00AM	Is the Options Market Predicting a Spike in Labcorp Holdings Stock? (Zacks)
Dec-12-25 09:19AM	How Is Labcorp Holdings' Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Dec-11-25 07:17PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Dec-10-25 11:34PM	3 Profitable Stocks That Fall Short (StockStory)
08:19PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Dec-09-25 11:38AM	Community Health Systems Stock Falls 7% Amid Debt & Other Pressures (Zacks)
Dec-07-25 11:04PM	3 Reasons to Avoid LH and 1 Stock to Buy Instead (StockStory)
Dec-04-25 02:17AM	CHS sells lab assets to Labcorp for $194M (Healthcare Dive)
Dec-03-25 11:30AM	Why Is Pediatrix Medical Group (MD) Up 11.1% Since Last Earnings Report? (Zacks)
Dec-02-25 04:15PM	Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp (Business Wire)
07:53AM	Should You Continue to Hold LH Stock in Your Portfolio? (Zacks)
Nov-28-25 11:30AM	Why Is CVS Health (CVS) Up 4.1% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Labcorp (LH) Up 8.1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-25-25 09:40AM	Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term (Zacks)
Nov-24-25 06:46PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
08:30AM	Labcorp Appoints Victor Bulto to Board of Directors (PR Newswire)
Nov-21-25 08:11AM	LH Shares Gain Following Publication of New Plasma Detect MRD Data (Zacks)
06:49AM	Labcorp Holdings Stock: Analyst Estimates & Ratings (Barchart)
Nov-19-25 07:04AM	Labcorp Plasma Detect Clinical Studies Featured in Nature Medicine and Clinical Cancer Research (PR Newswire)
Nov-14-25 06:16AM	Labcorp inks deal to buy Parkview Health outreach laboratory assets (MedTech Dive)
Nov-13-25 10:56PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-11-25 10:35PM	Q3 Earnings Highs And Lows: Labcorp (NYSE:LH) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Nov-06-25 05:50PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-05-25 07:32PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Nov-04-25 12:36AM	Labcorp's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Oct-31-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-30-25 03:14PM	Labcorp Holdings Inc (LH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-29-25 01:32AM	LH Q3 Deep Dive: Labcorp Sees Diagnostic Growth, Eyes Specialty Testing and Efficiency Initiatives (StockStory)
Oct-28-25 02:42PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research) -5.79%
12:11PM	Why Labcorp (LH) Stock Is Falling Today (StockStory)
10:01AM	LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:45AM	Here's Why Labcorp Holdings (LH) is a Strong Growth Stock (Zacks)
09:30AM	Labcorp (LH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:42AM	Labcorp (NYSE:LH) Reports Q3 In Line With Expectations (StockStory)
08:00AM	Labcorp Holdings (LH) Q3 Earnings Beat Estimates (Zacks)
06:57AM	Labcorp: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Labcorp Announces 2025 Third Quarter Results (PR Newswire)
Oct-27-25 06:57PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Oct-26-25 11:11PM	Labcorp (LH) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 06:43PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Oct-23-25 07:00AM	Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings (PR Newswire)

Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates through the Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments. The Dx segment includes routine and specialty esoteric testing. The BLS segment consists of central laboratory and ED businesses. The company was founded in 1995 and is headquartered in Burlington, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wilkinson Peter J	SVP, Chief Accounting Officer	Mar 27 '26	Sale	267.05	1,633	436,093	1,852	Mar 30 12:54 PM
Meltzer Jonathan C	EVP, Operations	Mar 27 '26	Sale	267.05	839	224,055	3,620	Mar 30 12:44 PM
Meltzer Jonathan C	Officer	Mar 27 '26	Proposed Sale	267.05	839	224,055		Mar 27 10:40 AM
Schechter Adam H	President & CEO	Mar 03 '26	Sale	279.96	8,705	2,437,047	80,773	Mar 05 08:57 AM
Schechter Adam H	Officer	Mar 03 '26	Proposed Sale	279.96	8,705	2,437,047		Mar 03 12:23 PM
van der Vaart Sandra D	EVP, Corporate Affairs	Feb 27 '26	Sale	284.91	548	156,000	2,579	Mar 03 10:41 AM
van der Vaart Sandra D	Officer	Feb 27 '26	Proposed Sale	284.67	548	156,000		Feb 27 09:40 AM
Caveney Brian J	EVP, Pres of ED, CMO & CSO	Feb 24 '26	Sale	286.31	1,500	429,458	30,107	Feb 26 08:25 AM
Caveney Brian J	Officer	Feb 24 '26	Proposed Sale	286.31	1,500	429,458		Feb 24 01:50 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Feb 19 '26	Sale	277.94	666	185,108	1,852	Feb 23 09:13 AM
Schechter Adam H	President & CEO	Feb 11 '26	Sale	284.38	5,273	1,499,536	87,343	Feb 13 01:13 PM
Meltzer Jonathan C	EVP, Operations	Feb 12 '26	Sale	290.42	87	25,267	2,782	Feb 13 01:11 PM
Meltzer Jonathan C	EVP, Operations	Feb 10 '26	Sale	276.79	91	25,188	2,696	Feb 12 03:44 PM
Meltzer Jonathan C	Officer	Feb 12 '26	Proposed Sale	290.42	87	25,267		Feb 12 09:49 AM
Schechter Adam H	Officer	Feb 11 '26	Proposed Sale	284.38	5,273	1,499,536		Feb 11 12:59 PM
Meltzer Jonathan C	EVP, Operations	Feb 09 '26	Sale	275.53	88	24,247	2,869	Feb 10 03:04 PM
Meltzer Jonathan C	Officer	Feb 10 '26	Proposed Sale	276.79	91	25,188		Feb 10 10:30 AM
Meltzer Jonathan C	Officer	Feb 09 '26	Proposed Sale	275.53	88	24,247		Feb 09 01:30 PM
Schechter Adam H	President & CEO	Nov 11 '25	Sale	262.75	5,745	1,509,499	87,574	Nov 13 08:47 AM
Schechter Adam H	Officer	Nov 11 '25	Proposed Sale	262.75	5,745	1,509,499		Nov 12 06:54 AM
Parham Richelle P	Director	Oct 31 '25	Sale	254.28	7,009	1,782,273	2,469	Nov 04 10:28 AM
Parham Richelle P	Director	Oct 31 '25	Proposed Sale	254.28	7,009	1,782,273		Oct 31 03:16 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Aug 13 '25	Option Exercise	131.43	3,903	512,971	6,177	Aug 15 10:55 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Aug 13 '25	Sale	271.42	3,903	1,059,371	2,274	Aug 15 10:55 AM
van der Vaart Sandra D	Officer	Aug 13 '25	Proposed Sale	271.42	3,903	1,059,371		Aug 13 12:49 PM
Schechter Adam H	President & CEO	Aug 11 '25	Sale	266.78	5,643	1,505,440	93,319	Aug 13 12:29 PM
Schechter Adam H	Officer	Aug 11 '25	Proposed Sale	266.78	5,643	1,505,440		Aug 11 09:50 AM
Gilliland Dwight Gary	Director	Jul 30 '25	Sale	264.95	2,000	529,900	6,656	Aug 01 08:44 AM
Wilkinson Peter J	SVP, Chief Accounting Officer	Jul 29 '25	Sale	261.02	202	52,727	1,852	Jul 31 08:38 AM
Gilliland Dwight Gary	Director	Jul 30 '25	Proposed Sale	264.95	2,000	529,900		Jul 30 04:45 PM
ANDERSON KERRII B	Director	Jul 24 '25	Sale	280.00	3,500	980,000	8,666	Jul 28 03:59 PM
ANDERSON KERRII B	Director	Jul 24 '25	Sale	280.00	3,500	980,000	8,666	Jul 28 03:59 PM
KERRII ANDERSON	Director	Jul 24 '25	Proposed Sale	250.51	3,500	876,785		Jul 24 04:24 PM
ANDERSON KERRII B	Director	Jul 01 '25	Sale	265.00	500	132,500	12,166	Jul 02 10:37 AM
ANDERSON KERRII B	Director	Jun 11 '25	Sale	260.00	500	130,000	12,666	Jun 12 10:07 AM
KERRII ANDERSON	Director	Jun 11 '25	Proposed Sale	259.37	1,000	259,370		Jun 11 04:29 PM
Caveney Brian J	EVP, Pres of ED, CMO & CSO	Jun 03 '25	Sale	247.00	2,000	494,000	30,067	Jun 05 08:19 AM
Caveney Brian J	Officer	Jun 03 '25	Proposed Sale	247.00	2,000	494,000		Jun 03 11:55 AM
EISENBERG GLENN A	Officer	May 13 '25	Proposed Sale	250.42	15,000	3,756,242		May 13 02:59 PM
Schechter Adam H	President & CEO	May 12 '25	Sale	248.73	6,105	1,518,497	98,962	May 13 10:01 AM
Schechter Adam H	Officer	May 12 '25	Proposed Sale	248.73	6,105	1,518,497		May 12 09:43 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	May 01 '25	Sale	238.36	1,900	452,884	2,244	May 05 12:45 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	May 01 '25	Sale	242.26	829	200,838	2,054	May 05 12:45 PM
van der Vaart Sandra D	Officer	May 01 '25	Proposed Sale	238.36	1,900	452,884		May 01 11:07 AM

Open in Screener

SERA

Sera Prognostics Inc

Apr 02 • 04:00PM ET

2.01

-0.06 -2.90 %

Healthcare • Medical Devices • USA • NASD

SERA Sera Prognostics Inc daily Stock Chart

Peers: ILMN NTRA GH BIO EXAS ONC CDNA QDEL RCKT VERU

| Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-0.67	Insider Own	30.79%	Shs Outstand	37.98M	Perf Week	1.01%
Market Cap	78.68M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	-1.54%	Shs Float	27.09M	Perf Month	-0.50%
Enterprise Value	41.82M	PEG	-	EPS next Q	-0.17	Inst Own	40.85%	Short Float	0.91%	Perf Quarter	-31.86%
Income	-31.93M	P/S	983.50	EPS this Y	-0.50%	Inst Trans	-1.06%	Short Ratio	4.00	Perf Half Y	-31.86%
Sales	0.08M	P/B	1.04	EPS next Y	0.00%	ROA	-36.43%	Short Interest	0.25M	Perf YTD	-31.86%
Book/sh	1.94	P/C	2.01	EPS next 5Y	17.80%	ROE	-51.83%	52W High	4.09 -50.86%	Perf Year	-41.74%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	22.30% -0.71%	ROIC	-41.07%	52W Low	1.37 46.72%	Perf 3Y	-47.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-32.89% 26.51%	Gross Margin	-1119.75%	Volatility	8.31% 10.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	522.75	EPS Y/Y TTM	32.03%	Oper. Margin	-45066.67%	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.69	Sales Y/Y TTM	5.19%	Profit Margin	-39417.28%	RSI (14)	46.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.69	EPS Q/Q	37.62%	SMA20	2.88%	Beta	1.06	Target Price	5.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-58.33%	SMA50	-13.89%	Rel Volume	0.24	Prev Close	2.07
Employees	72	LT Debt/Eq	0.03	Earnings	Mar 18 AMC	SMA200	-29.51%	Avg Volume	61.85K	Price	2.01
IPO	Jul 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.34% -68.55%	Trades		Volume	14,750	Change	-2.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Initiated	Jefferies	Buy	$5
Mar-30-22	Downgrade	Citigroup	Buy → Neutral	$18 → $4
Nov-19-21	Initiated	Oppenheimer	Outperform	$19
Oct-15-21	Resumed	Cowen	Outperform

Mar-19-26 08:30AM	Sera Prognostics, Inc. Q4 2025 Earnings Call Summary (Moby) -6.28%
Mar-18-26 11:00PM	Sera Prognostics Inc (SERA) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS (PR Newswire)
Mar-17-26 09:23AM	Sera Prognostics Inc (SERA) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-09-26 05:20PM	LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.18%
05:55PM	Loading…
Mar-04-26 05:55PM	Enhabit (EHAB) Matches Q4 Earnings Estimates (Zacks)
08:05AM	SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026 (PR Newswire)
Feb-24-26 09:08AM	Enhabit (EHAB) Surges 22.6%: Is This an Indication of Further Gains? (Zacks) -8.16%
Feb-17-26 08:05AM	SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE (PR Newswire)
Jan-07-26 08:30AM	Landmark Study Finds PreTRM Blood Test Reduces Earliest Preterm Births and Newborn Complications (PR Newswire) +11.49%
Nov-26-25 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's Why (Zacks)
Nov-24-25 08:00AM	Sera Announces Publication Acceptance for PRIME Study (PR Newswire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
Nov-14-25 12:05AM	Sera Prognostics Inc (SERA) Q3 2025 Earnings Call Highlights: Strategic Medicaid Pilots and ... (GuruFocus.com)
Nov-13-25 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.45%
04:05PM	Loading…
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
Nov-04-25 10:05AM	Premier, Inc. (PINC) Tops Q1 Earnings and Revenue Estimates (Zacks) -5.63%
Oct-30-25 04:05PM	SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025 (PR Newswire)
Oct-29-25 07:40AM	CVS Health (CVS) Surpasses Q3 Earnings and Revenue Estimates (Zacks) -6.93%
Oct-01-25 08:05AM	Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer (PR Newswire)
Aug-28-25 08:05AM	SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE (PR Newswire) +8.45%
Aug-06-25 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +12.24% -5.45%
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
Jul-29-25 04:05PM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025 (PR Newswire) -7.64%
May-29-25 09:35AM	After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA) (Zacks)
08:30AM	SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES (PR Newswire)
May-14-25 04:05PM	SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE (PR Newswire) +6.00%
May-13-25 09:35AM	Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround (Zacks)
May-08-25 04:40PM	SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER (PR Newswire) -11.67%
03:36AM	Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
05:55PM	Loading…
May-07-25 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS (PR Newswire)
Apr-24-25 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025 (PR Newswire)
Apr-15-25 01:54AM	Sera Prognostics: Initiating With Hold, Potential Of PreTRM Test, But Uncertain Commercial Timeline (Seeking Alpha)
Mar-19-25 07:13PM	Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.07%
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:10PM	SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN (PR Newswire)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Mar-11-25 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025 (PR Newswire)
Feb-21-25 08:30AM	Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference (PR Newswire)
Feb-10-25 10:41PM	Sera Prognostics Announces Pricing of $50 Million Public Offering (PR Newswire) -9.44%
04:01PM	Sera Prognostics Announces Proposed Public Offering (PR Newswire)
Jan-27-25 05:02PM	Sera Prognostics to Host Virtual R&D Day on January 31 (PR Newswire) -5.19%
Jan-06-25 08:30AM	Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-04-24 04:01PM	Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting (PR Newswire) +14.78%
Dec-02-24 08:30AM	Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-26-24 05:00AM	5 investing trends for 2025and 15 stocks to help you bet on them (Fortune)
Nov-15-24 08:30AM	Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire)
Nov-06-24 06:00PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.25% -12.70%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Oct-28-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024 (PR Newswire)
Sep-04-24 04:53PM	Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 08:30AM	Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024 (PR Newswire)
Aug-07-24 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Jul-25-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 (PR Newswire)
Jul-09-24 08:30AM	Sera Prognostics PreTRM Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial (PR Newswire)
Jul-01-24 08:30AM	SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION (PR Newswire)
Jun-16-24 06:17AM	3 Stocks Under $10 With the Potential to Make You a Millionaire (InvestorPlace)
May-28-24 08:30AM	SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES (PR Newswire)
May-10-24 03:10PM	Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves (GuruFocus.com) -5.41%
May-09-24 10:44AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.27%
May-08-24 08:57PM	SERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Apr-29-24 02:15PM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024 (PR Newswire)
Mar-29-24 01:32AM	Chief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-27-24 01:27AM	Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-25-24 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know (Zacks) -8.50%
Mar-21-24 09:57AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 08:54PM	SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:33PM	Sera Prognostics Inc Reports Modest Revenue Growth Amid Operational Streamlining (GuruFocus.com)
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey)
Mar-04-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024 (PR Newswire)
Feb-29-24 11:14AM	Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Dec-11-23 12:00PM	Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy (Zacks)
Dec-06-23 01:19PM	Why Is Sera Prognostics (SERA) Stock Up 260% Today? (InvestorPlace) +161.43%
08:30AM	SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS (PR Newswire)
Nov-22-23 01:00PM	SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE (PR Newswire)
Nov-12-23 10:59AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:29PM	Sera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ... (GuruFocus.com) -7.61%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Oct-25-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023 (PR Newswire) +6.06%
Sep-21-23 08:30AM	SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023 (PR Newswire)
Aug-31-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.32%
Aug-30-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-23 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jul-31-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023 (PR Newswire)
May-25-23 04:15PM	Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue (PR Newswire) -5.08%
May-15-23 05:15PM	Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO (PR Newswire)
May-10-23 06:05PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
May-04-23 07:31AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Apr-27-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023 (PR Newswire)
Apr-24-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-27-23 12:00PM	All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy (Zacks)
02:27AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:29AM	Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations (Simply Wall St.)

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT HARRISON	Officer	Mar 24 '26	Proposed Sale	1.82	2,000	3,640		Mar 24 04:29 PM
Lindgardt Zhenya	Chief Executive Officer	Mar 10 '26	Sale	1.90	22,639	43,014	741,287	Mar 12 08:14 PM
Lindgardt Zhenya	Chief Executive Officer	Mar 11 '26	Sale	2.04	2,973	6,065	738,314	Mar 12 08:14 PM
Kearney Paul	Chief Data Officer	Mar 11 '26	Sale	2.04	1,396	2,848	163,961	Mar 12 08:14 PM
Jackson Benjamin	General Counsel	Mar 11 '26	Sale	2.04	1,027	2,095	114,720	Mar 12 08:13 PM
Harrison Robert Gardner	Chief Information Officer	Mar 11 '26	Sale	2.04	716	1,461	76,712	Mar 12 08:12 PM
Boniface John J.	Chief Scientific Officer	Mar 11 '26	Sale	2.04	1,517	3,095	145,842	Mar 12 08:12 PM
Aerts Austin	Chief Financial Officer	Mar 10 '26	Sale	1.90	6,069	11,531	265,471	Mar 12 08:12 PM
Aerts Austin	Chief Financial Officer	Mar 11 '26	Sale	2.04	1,019	2,079	264,452	Mar 12 08:12 PM
Lindgardt Zhenya	Officer	Mar 11 '26	Proposed Sale	2.04	2,973	6,068		Mar 12 08:10 PM
Kearney Paul	Officer	Mar 11 '26	Proposed Sale	2.04	1,396	2,850		Mar 12 08:09 PM
Jackson Benjamin	Officer	Mar 11 '26	Proposed Sale	2.04	1,027	2,096		Mar 12 08:09 PM
Harrison Robert Gardner	Officer	Mar 11 '26	Proposed Sale	2.04	716	1,462		Mar 12 08:08 PM
Boniface John J.	Officer	Mar 11 '26	Proposed Sale	2.04	1,517	3,097		Mar 12 08:08 PM
Aerts Austin	Officer	Mar 11 '26	Proposed Sale	2.04	1,019	2,080		Mar 12 08:07 PM
Lindgardt Zhenya	Officer	Mar 10 '26	Proposed Sale	1.90	22,639	43,028		Mar 12 08:07 PM
Aerts Austin	Officer	Mar 10 '26	Proposed Sale	1.90	6,069	11,535		Mar 12 08:06 PM
Kearney Paul	Chief Data Officer	Mar 09 '26	Sale	1.96	2,026	3,971	165,357	Mar 10 05:54 PM
Jackson Benjamin	General Counsel	Mar 09 '26	Sale	1.96	3,119	6,113	115,747	Mar 10 05:53 PM
Harrison Robert Gardner	Chief Information Officer	Mar 09 '26	Sale	1.96	3,360	6,586	77,428	Mar 10 05:53 PM
Boniface John J.	Chief Scientific Officer	Mar 09 '26	Sale	1.96	3,038	5,954	147,359	Mar 10 05:53 PM
Aerts Austin	Chief Financial Officer	Mar 09 '26	Sale	1.96	674	1,321	271,540	Mar 10 05:53 PM
Kearney Paul	Officer	Mar 09 '26	Proposed Sale	1.96	2,026	3,977		Mar 10 05:51 PM
Jackson Benjamin	Officer	Mar 09 '26	Proposed Sale	1.96	3,119	6,123		Mar 10 05:51 PM
Harrison Robert Gardner	Officer	Mar 09 '26	Proposed Sale	1.96	3,360	6,596		Mar 10 05:51 PM
Boniface John J.	Officer	Mar 09 '26	Proposed Sale	1.96	3,038	5,964		Mar 10 05:50 PM
Aerts Austin	Officer	Mar 09 '26	Proposed Sale	1.96	674	1,323		Mar 10 05:50 PM
Lawrence Sandra AJ	Director	Mar 06 '26	Sale	1.95	1,560	3,042	18,033	Mar 06 07:25 PM
SANDRA AJ LAWRENCE	Director	Mar 06 '26	Proposed Sale	2.00	1,560	3,120		Mar 06 04:30 PM
Harrison Robert Gardner	Chief Information Officer	Feb 24 '26	Sale	2.34	2,000	4,680	80,788	Feb 24 06:10 PM
ROBERT HARRISON	Officer	Feb 24 '26	Proposed Sale	2.45	2,000	4,900		Feb 24 04:28 PM
Harrison Robert Gardner	Chief Information Officer	Jan 27 '26	Sale	2.97	2,000	5,940	82,788	Jan 27 05:12 PM
ROBERT HARRISON	Officer	Jan 27 '26	Proposed Sale	3.09	2,000	6,180		Jan 27 04:18 PM
Harrison Robert Gardner	Chief Information Officer	Dec 30 '25	Sale	3.00	2,000	6,000	84,788	Dec 30 06:41 PM
ROBERT GARDNER HARRISON	Officer	Dec 30 '25	Proposed Sale	3.27	2,000	6,540		Dec 30 04:24 PM
Lindgardt Zhenya	Chief Executive Officer	Dec 10 '25	Sale	3.31	4,155	13,753	763,926	Dec 11 07:58 PM
Kearney Paul	Chief Data Officer	Dec 10 '25	Sale	3.31	1,213	4,015	167,383	Dec 11 07:57 PM
Jackson Benjamin	General Counsel	Dec 10 '25	Sale	3.31	892	2,953	118,866	Dec 11 07:57 PM
Harrison Robert Gardner	Chief Information Officer	Dec 10 '25	Sale	3.31	616	2,039	86,788	Dec 11 07:56 PM
Boniface John J.	Chief Scientific Officer	Dec 10 '25	Sale	3.31	1,332	4,409	150,397	Dec 11 07:56 PM
Aerts Austin	Chief Financial Officer	Dec 10 '25	Sale	3.31	873	2,890	272,214	Dec 11 07:56 PM
Lindgardt Zhenya	Officer	Dec 10 '25	Proposed Sale	3.31	4,155	13,741		Dec 11 07:54 PM
Kearney Paul	Officer	Dec 10 '25	Proposed Sale	3.31	1,213	4,012		Dec 11 07:54 PM
Jackson Benjamin	Officer	Dec 10 '25	Proposed Sale	3.31	892	2,950		Dec 11 07:54 PM
Harrison Robert Gardner	Officer	Dec 10 '25	Proposed Sale	3.31	616	2,037		Dec 11 07:53 PM
Boniface John J.	Officer	Dec 10 '25	Proposed Sale	3.31	1,332	4,405		Dec 11 07:53 PM
Aerts Austin	Officer	Dec 10 '25	Proposed Sale	3.31	873	2,887		Dec 11 07:53 PM
Lindgardt Zhenya	Chief Executive Officer	Dec 09 '25	Sale	3.04	28,215	85,774	768,081	Dec 10 07:24 PM
Aerts Austin	Chief Financial Officer	Dec 09 '25	Sale	3.04	5,232	15,905	273,087	Dec 10 07:24 PM
Lindgardt Zhenya	Officer	Dec 09 '25	Proposed Sale	3.04	28,215	85,838		Dec 10 07:23 PM
Aerts Austin	Officer	Dec 09 '25	Proposed Sale	3.04	5,232	15,917		Dec 10 07:23 PM
Lawrence Sandra AJ	Director	Dec 08 '25	Sale	3.05	1,560	4,758	19,593	Dec 08 07:06 PM
SANDRA AJ LAWRENCE	Director	Dec 08 '25	Proposed Sale	3.08	1,560	4,805		Dec 08 04:38 PM
Mirza Mansoor Raza	Director	Dec 05 '25	Sale	3.05	292	891	57,740	Dec 05 05:25 PM
Mirza Mansoor Raza	Director	Dec 05 '25	Proposed Sale	3.05	292	892		Dec 05 05:24 PM
Harrison Robert Gardner	Chief Information Officer	Dec 02 '25	Sale	2.93	2,000	5,860	87,404	Dec 03 04:14 PM
Kearney Paul	Chief Data Officer	Dec 02 '25	Option Exercise	1.62	32,203	52,169	200,799	Dec 03 04:14 PM
Kearney Paul	Chief Data Officer	Dec 02 '25	Sale	2.94	32,203	94,677	168,596	Dec 03 04:14 PM
PAUL KEARNEY	Officer	Dec 02 '25	Proposed Sale	2.94	32,203	94,609		Dec 02 05:40 PM
ROBERT GARDNER HARRISON	Officer	Dec 02 '25	Proposed Sale	3.21	2,000	6,420		Dec 02 04:22 PM
Kearney Paul	Chief Data Officer	Nov 26 '25	Option Exercise	1.62	1,986	3,217	170,582	Nov 26 06:53 PM
Kearney Paul	Chief Data Officer	Nov 26 '25	Sale	3.51	1,986	6,971	168,596	Nov 26 06:53 PM
PAUL KEARNEY	Officer	Nov 26 '25	Proposed Sale	3.40	34,189	116,243		Nov 26 04:18 PM
Lindgardt Zhenya	Chief Executive Officer	Nov 10 '25	Sale	2.62	11,594	30,376	796,296	Nov 12 04:25 PM
Kearney Paul	Chief Data Officer	Nov 10 '25	Sale	2.62	7,073	18,531	168,596	Nov 12 04:24 PM
Jackson Benjamin	General Counsel	Nov 10 '25	Sale	2.62	7,059	18,495	119,758	Nov 12 04:24 PM
Harrison Robert Gardner	Chief Information Officer	Nov 10 '25	Sale	2.62	6,528	17,103	89,404	Nov 12 04:24 PM
Boniface John J.	Chief Scientific Officer	Nov 10 '25	Sale	2.62	7,767	20,350	151,726	Nov 12 04:23 PM
Aerts Austin	Chief Financial Officer	Nov 10 '25	Sale	2.62	6,351	16,640	278,319	Nov 12 04:23 PM
Lindgardt Zhenya	Officer	Nov 10 '25	Proposed Sale	2.62	11,594	30,408		Nov 12 04:22 PM
Kearney Paul	Officer	Nov 10 '25	Proposed Sale	2.62	7,073	18,550		Nov 12 04:21 PM
Jackson Benjamin	Officer	Nov 10 '25	Proposed Sale	2.62	7,059	18,514		Nov 12 04:21 PM
Harrison Robert Gardner	Officer	Nov 10 '25	Proposed Sale	2.62	6,528	17,121		Nov 12 04:21 PM
Boniface John J.	Officer	Nov 10 '25	Proposed Sale	2.62	7,767	20,371		Nov 12 04:21 PM
Aerts Austin	Officer	Nov 10 '25	Proposed Sale	2.62	6,351	16,657		Nov 12 04:20 PM
Mirza Mansoor Raza	Director	Nov 05 '25	Sale	3.04	221	672	58,032	Nov 06 05:05 PM
Mirza Mansoor Raza	Director	Nov 05 '25	Proposed Sale	3.04	221	672		Nov 06 05:04 PM
Harrison Robert Gardner	Chief Information Officer	Nov 04 '25	Sale	3.07	2,000	6,140	95,932	Nov 04 06:35 PM
ROBERT GARDNER HARRISON	Officer	Nov 04 '25	Proposed Sale	3.20	2,000	6,400		Nov 04 04:32 PM
Harrison Robert Gardner	Chief Information Officer	Oct 07 '25	Sale	3.18	2,000	6,360	97,932	Oct 08 04:35 PM
ROBERT GARDNER HARRISON	Officer	Oct 07 '25	Proposed Sale	3.26	2,000	6,520		Oct 07 04:18 PM
Mirza Mansoor Raza	Director	Oct 06 '25	Sale	3.16	227	717	58,253	Oct 06 04:15 PM
Mirza Mansoor Raza	Director	Oct 06 '25	Proposed Sale	3.16	227	718		Oct 06 04:13 PM
Lindgardt Zhenya	Chief Executive Officer	Sep 11 '25	Sale	3.13	3,246	10,160	807,890	Sep 12 04:36 PM
Kearney Paul	Chief Data Officer	Sep 11 '25	Sale	3.13	1,271	3,978	175,669	Sep 12 04:36 PM
Jackson Benjamin	General Counsel	Sep 11 '25	Sale	3.13	934	2,923	126,817	Sep 12 04:35 PM
Harrison Robert Gardner	Chief Information Officer	Sep 11 '25	Sale	3.13	645	2,019	99,932	Sep 12 04:35 PM
Boniface John J.	Chief Scientific Officer	Sep 11 '25	Sale	3.13	1,395	4,366	159,493	Sep 12 04:35 PM
Aerts Austin	Chief Financial Officer	Sep 11 '25	Sale	3.13	915	2,864	284,670	Sep 12 04:34 PM
Lindgardt Zhenya	Officer	Sep 11 '25	Proposed Sale	3.13	3,246	10,156		Sep 12 04:33 PM
Kearney Paul	Officer	Sep 11 '25	Proposed Sale	3.13	1,271	3,977		Sep 12 04:33 PM
Jackson Benjamin	Officer	Sep 11 '25	Proposed Sale	3.13	934	2,922		Sep 12 04:32 PM
Harrison Robert Gardner	Officer	Sep 11 '25	Proposed Sale	3.13	645	2,018		Sep 12 04:32 PM
Boniface John J.	Officer	Sep 11 '25	Proposed Sale	3.13	1,395	4,365		Sep 12 04:32 PM
Aerts Austin	Officer	Sep 11 '25	Proposed Sale	3.13	915	2,863		Sep 12 04:31 PM
Lindgardt Zhenya	Chief Executive Officer	Sep 09 '25	Sale	3.15	21,158	66,648	811,136	Sep 09 07:31 PM
Aerts Austin	Chief Financial Officer	Sep 09 '25	Sale	3.15	5,263	16,578	285,585	Sep 09 07:30 PM
Lindgardt Zhenya	Officer	Sep 09 '25	Proposed Sale	3.15	21,158	66,572		Sep 09 07:30 PM
Aerts Austin	Officer	Sep 09 '25	Proposed Sale	3.15	5,263	16,560		Sep 09 07:30 PM
Lawrence Sandra AJ	Director	Sep 09 '25	Sale	3.05	3,899	11,892	18,814	Sep 09 06:51 PM

Open in Screener

PSNL

Personalis Inc

Apr 02 • 04:00PM ET

6.58

+0.02 0.30 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN NTRA CDNA GH FLGT BNR EXAS FATE TXG MYGN

| Held by: ARKG VTI IWM VXF IBB IWN VTWO DFAS VHT DFMC

Index	RUT	P/E	-	EPS (ttm)	-0.91	Insider Own	40.59%	Shs Outstand	102.48M	Perf Week	-10.11%
Market Cap	688.48M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	0.44%	Shs Float	62.17M	Perf Month	-26.32%
Enterprise Value	489.34M	PEG	-	EPS next Q	-0.27	Inst Own	55.97%	Short Float	17.96%	Perf Quarter	-17.34%
Income	-81.27M	P/S	9.88	EPS this Y	-18.43%	Inst Trans	18.86%	Short Ratio	7.64	Perf Half Y	-4.78%
Sales	69.65M	P/B	2.58	EPS next Y	12.81%	ROA	-26.89%	Short Interest	11.17M	Perf YTD	-17.34%
Book/sh	2.55	P/C	2.87	EPS next 5Y	16.49%	ROE	-35.02%	52W High	11.50 -42.78%	Perf Year	84.83%
Cash/sh	2.29	P/FCF	-	EPS past 3/5Y	28.38% 2.91%	ROIC	-27.65%	52W Low	2.83 132.82%	Perf 3Y	138.41%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	2.30% -2.40%	Gross Margin	22.65%	Volatility	9.60% 7.98%	Perf 5Y	-72.73%
Dividend TTM	-	EV/Sales	7.03	EPS Y/Y TTM	33.47%	Oper. Margin	-126.43%	ATR (14)	0.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.61	Sales Y/Y TTM	-17.69%	Profit Margin	-116.69%	RSI (14)	38.93	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	6.74	EPS Q/Q	-14.46%	SMA20	-8.22%	Beta	2.25	Target Price	11.43
Payout	-	Debt/Eq	0.16	Sales Q/Q	3.24%	SMA50	-20.16%	Rel Volume	0.67	Prev Close	6.56
Employees	260	LT Debt/Eq	0.13	Earnings	Feb 26 AMC	SMA200	-12.80%	Avg Volume	1.46M	Price	6.58
IPO	Jun 20, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.82% 1.73%	Trades		Volume	972,887	Change	0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$11
May-15-25	Initiated	Guggenheim	Buy	$6
Mar-17-25	Initiated	Craig Hallum	Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22

Show Previous Ratings

Apr-01-26 04:01PM	Personalis to Participate in the 25th Annual Needham Virtual Conference (Business Wire)
Mar-17-26 04:00PM	Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption (Business Wire)
Mar-12-26 06:00AM	Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal (Business Wire) -17.11%
Feb-27-26 08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
04:30AM	Personalis Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Loading…
12:02AM	Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... (GuruFocus.com)
Feb-26-26 05:30PM	Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +8.66%
04:26PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
Feb-24-26 07:30PM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-17-26 04:01PM	Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference (Business Wire) +5.02%
Feb-12-26 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -5.73%
Feb-10-26 09:18AM	Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test (Benzinga) +10.09%
06:00AM	Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance (Business Wire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool) -9.67%
08:18PM	Loading…
Feb-02-26 08:18PM	Personalis, Inc. (PSNL): A Bull Case Theory (Insider Monkey)
06:00AM	Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Jan-28-26 04:01PM	Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-12-26 04:00PM	Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker (Business Wire) +5.80%
Jan-08-26 08:00AM	Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire) -10.43%
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 12:19PM	Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) (Insider Monkey)
Dec-17-25 06:00AM	Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Dec-11-25 09:00AM	New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer (Business Wire)
Nov-18-25 04:01PM	Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire) +8.14%
Nov-05-25 12:11AM	Personalis Inc (PSNL) Q3 2025 Earnings Call Highlights: Strong Clinical Adoption Amid Revenue ... (GuruFocus.com) -12.26%
Nov-04-25 05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2025 Financial Results (Business Wire)
07:51AM	Loading…
Nov-03-25 07:51AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q3 2025 Result (GuruFocus.com) -6.64%
Oct-21-25 04:01PM	Personalis to Announce Third Quarter 2025 Financial Results (Business Wire) -5.43% -6.74%
Oct-17-25 03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks) -11.19%
Oct-16-25 09:00AM	Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing (Business Wire) +20.52%
Sep-15-25 05:35PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks) +13.17%
Sep-10-25 04:05PM	CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test (Business Wire)
Sep-03-25 04:05PM	Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing (Business Wire)
Aug-27-25 04:01PM	Personalis to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 09:35AM	Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) (Zacks) +5.69%
Aug-12-25 09:35AM	After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) (Zacks)
Aug-08-25 12:00PM	All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy (Zacks)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-05-25 04:10PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance) -21.90%
04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 09:58AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q2 2025 Result (GuruFocus.com)
Jul-22-25 04:01PM	Personalis to Announce Second Quarter 2025 Financial Results (Business Wire) +5.13%
Jul-18-25 04:00PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
Jul-09-25 04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-03-25 07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-17-25 10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-03-25 04:00PM	Personalis' NeXT Personal Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO (Business Wire) +5.53%
Jun-02-25 04:00PM	New Data Shows NeXT Personal Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse (Business Wire)
May-22-25 06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection (Business Wire)
May-14-25 04:01PM	Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference (Business Wire) -6.23%
May-07-25 03:23AM	Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +21.00%
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.10%
04:01PM	Personalis Reports First Quarter 2025 Financial Results (Business Wire)
May-05-25 10:12AM	Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 08:05PM	Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-28-25 05:00PM	Personalis' NeXT Personal Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study (Business Wire)
Apr-22-25 06:47PM	Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey) +7.91% +7.92%
04:01PM	Personalis to Announce First Quarter 2025 Financial Results (Business Wire)
06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 04:01PM	Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-03-25 06:00AM	New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection (Business Wire)
Feb-28-25 04:00AM	Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:20PM	Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.36%
04:21PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:09AM	Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.91%
Feb-20-25 10:00AM	Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -6.78%
Feb-18-25 04:01PM	Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference (Business Wire) +9.62%
Feb-13-25 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire) +7.08% +10.42%
Jan-28-25 04:01PM	Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire) -6.37% -7.90%
Jan-20-25 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's Why (Zacks)
Jan-13-25 11:09AM	Researchers find ctDNA test predicts lung cancer outcomes in study (Medical Device Network)
05:00AM	New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer (Business Wire)
Jan-07-25 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue (Business Wire) -6.71% -6.35%
Dec-21-24 07:30AM	Personalis price target raised to $8 from $7 at BTIG (TipRanks)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) +9.32%
Dec-19-24 09:00AM	Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna (Business Wire) +47.75%
Dec-18-24 03:00AM	Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma (Insider Monkey) -7.29%
Dec-16-24 08:00AM	Personalis and Tempus Expand Collaboration to Biopharma (Business Wire)
Nov-20-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -6.23%
Nov-07-24 10:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... (GuruFocus.com) -22.58%
Nov-06-24 05:25PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 04:01PM	Personalis to Present at the Stifel 2024 Healthcare Conference (Business Wire) +12.80%
08:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-23-24 04:01PM	Personalis to Announce Third Quarter 2024 Financial Results (Business Wire)
Sep-16-24 09:00AM	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal MRD Test (Business Wire)
Aug-22-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -9.94%
Aug-21-24 06:13PM	Why Tempus AI Stock Skyrocketed Nearly 22% Today (Motley Fool) +11.42%
Aug-19-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Option Exercise	9.16	1,201	11,001	165,659	Jan 23 06:03 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Sale	11.50	1,201	13,812	164,458	Jan 23 06:03 PM
AARON L TACHIBANA	Officer	Jan 22 '26	Proposed Sale	9.65	40,000	386,000		Jan 22 04:34 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Option Exercise	9.16	103,668	949,599	268,126	Nov 28 05:09 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Sale	10.78	103,668	1,117,541	164,458	Nov 28 05:09 PM
AARON L TACHIBANA	Officer	Nov 25 '25	Proposed Sale	9.99	103,668	1,035,643		Nov 25 04:51 PM
Hall Christopher M	PRESIDENT AND CEO	Nov 03 '25	Sale	8.99	29,612	266,212	148,486	Nov 05 04:05 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 28 '25	Sale	6.57	452	2,970	124,505	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	Jul 28 '25	Sale	6.57	641	4,211	164,458	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	May 16 '25	Sale	4.95	1,291	6,390	165,099	May 20 05:53 PM
Moore Stephen Michael	SVP and Chief Legal Officer	May 16 '25	Sale	4.95	1,675	8,291	64,200	May 20 05:51 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	May 16 '25	Sale	4.95	910	4,504	124,957	May 20 05:50 PM

Open in Screener

NTRA

Natera Inc

Apr 02 • 04:00PM ET

207.98

+4.77 2.35 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP IWF IWR XBI VHT

Index	-	P/E	-	EPS (ttm)	-1.54	Insider Own	4.86%	Shs Outstand	139.69M	Perf Week	6.03%
Market Cap	29.48B	Forward P/E	-	EPS next Y	-0.61	Insider Trans	-12.55%	Shs Float	134.84M	Perf Month	2.44%
Enterprise Value	28.62B	PEG	-	EPS next Q	-0.54	Inst Own	92.53%	Short Float	2.45%	Perf Quarter	-9.21%
Income	-208.16M	P/S	12.78	EPS this Y	-19.70%	Inst Trans	0.76%	Short Ratio	2.76	Perf Half Y	28.69%
Sales	2.31B	P/B	16.97	EPS next Y	66.46%	ROA	-9.93%	Short Interest	3.31M	Perf YTD	-9.21%
Book/sh	12.26	P/C	27.39	EPS next 5Y	-	ROE	-14.32%	52W High	256.36 -18.87%	Perf Year	45.24%
Cash/sh	7.59	P/FCF	270.16	EPS past 3/5Y	35.09% 11.70%	ROIC	-11.37%	52W Low	125.38 65.88%	Perf 3Y	274.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	41.14% 42.61%	Gross Margin	64.67%	Volatility	5.29% 4.04%	Perf 5Y	102.08%
Dividend TTM	-	EV/Sales	12.41	EPS Y/Y TTM	-0.51%	Oper. Margin	-13.27%	ATR (14)	8.90	Perf 10Y	2070.98%
Dividend Ex-Date	-	Quick Ratio	3.24	Sales Y/Y TTM	35.90%	Profit Margin	-9.03%	RSI (14)	55.28	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	182.67%	SMA20	5.63%	Beta	1.68	Target Price	259.30
Payout	-	Debt/Eq	0.13	Sales Q/Q	39.79%	SMA50	-0.33%	Rel Volume	1.07	Prev Close	203.21
Employees	6140	LT Debt/Eq	0.07	Earnings	Feb 26 AMC	SMA200	7.94%	Avg Volume	1.20M	Price	207.98
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	170.30% 10.18%	Trades		Volume	1,279,562	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90

Show Previous Ratings

Mar-31-26 06:00AM	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery (Business Wire) +7.04%
Mar-16-26 06:00AM	Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers (Business Wire) +5.23%
Mar-12-26 08:00AM	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis (Business Wire)
08:00AM	MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 (PR Newswire)
Mar-09-26 12:41AM	3 Healthcare Stocks to Target This Week (StockStory)
07:10AM	Loading…
Mar-04-26 07:10AM	Signatera Oncology Test Drives Natera's (NTRA) Growth (Insider Monkey)
Mar-03-26 03:35PM	Natera (NTRA) Stock Trades Up, Here Is Why (StockStory)
Feb-27-26 12:40PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
10:05AM	Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation (Business Wire)
08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:07AM	Natera Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... (GuruFocus.com)
Feb-26-26 11:53PM	Natera, Inc. (NTRA) Announces Results From the SINERGY Trial (Insider Monkey)
06:45PM	Natera (NTRA) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:30PM	Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:58PM	Loading…
04:58PM	Natera: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 10:28PM	Natera Earnings: What To Look For From NTRA (StockStory)
06:00AM	Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer (Business Wire)
Feb-23-26 09:15AM	Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat)
08:10AM	Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-17-26 04:01PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ... (GuruFocus.com)
09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 (Business Wire)
Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
06:00AM	Loading…
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-21-25 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 31 '26	Option Exercise	9.59	41,708	399,980	2,352,480	Apr 01 09:05 PM
SOLOMON MOSHKEVICH	Officer	Apr 01 '26	Proposed Sale	202.30	3,000	606,899		Apr 01 04:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 18 '26	Sale	198.17	3,070	608,370	259,255	Mar 20 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 20 '26	Sale	199.95	1,500	299,931	21,032	Mar 20 09:05 PM
Sheena Jonathan	Director	Mar 20 '26	Proposed Sale	200.25	6,000	1,201,500		Mar 20 01:07 PM
Sheena Jonathan	Director	Mar 18 '26	Proposed Sale	198.16	12,441	2,465,309		Mar 18 11:19 AM
Chapman Rowan E	Director	Mar 13 '26	Sale	191.38	122	23,348	5,752	Mar 17 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 12 '26	Option Exercise	9.59	75,000	719,250	2,385,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 13 '26	Option Exercise	9.59	75,000	719,250	2,385,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 16 '26	Option Exercise	9.59	50,000	479,500	2,360,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 12 '26	Sale	190.59	75,000	14,294,119	2,310,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 13 '26	Sale	189.01	75,000	14,175,379	2,310,772	Mar 16 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 16 '26	Sale	196.28	50,000	9,813,883	2,310,772	Mar 16 09:05 PM
ROWAN EMMA CHAPMAN	Director	Mar 13 '26	Proposed Sale	191.38	122	23,348		Mar 13 04:19 PM
MATTHEW RABINOWITZ	Director	Mar 12 '26	Proposed Sale	196.61	200,000	39,322,000		Mar 12 04:29 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 10 '26	Sale	204.13	785	160,244	63,354	Mar 11 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 10 '26	Sale	204.13	5,623	1,147,838	156,607	Mar 11 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 10 '26	Sale	204.13	1,745	356,212	233,285	Mar 11 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 10 '26	Sale	204.13	127	25,925	262,325	Mar 11 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 10 '26	Sale	204.13	707	144,322	189,199	Mar 11 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 10 '26	Sale	204.13	915	186,781	150,882	Mar 11 06:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 06 '26	Option Exercise	19.68	5,598	110,169	241,683	Mar 10 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 06 '26	Sale	196.08	8,398	1,646,696	233,285	Mar 10 09:05 PM
DANIEL RABINOWITZ	Officer	Mar 06 '26	Proposed Sale	197.14	16,798	3,311,558		Mar 06 04:29 PM
Sheena Jonathan	CO-FOUNDER	Mar 02 '26	Sale	200.23	3,070	614,710	262,194	Mar 03 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 02 '26	Sale	200.02	3,950	790,095	156,607	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Option Exercise	9.59	5,125	49,149	153,023	Mar 03 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 02 '26	Sale	199.85	3,000	599,545	150,023	Mar 03 09:05 PM
STEVEN L CHAPMAN	Officer	Mar 02 '26	Proposed Sale	200.02	3,950	790,095		Mar 02 04:12 PM
SOLOMON MOSHKEVICH	Officer	Mar 02 '26	Proposed Sale	199.85	3,000	599,545		Mar 02 04:11 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 02 '26	Sale	231.44	3,000	694,309	139,486	Feb 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 03 '26	Sale	230.77	1,639	378,229	137,847	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 02 '26	Sale	230.72	85,299	19,680,040	127,881	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 03 '26	Sale	230.77	4,725	1,090,379	123,156	Feb 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	227.83	6,939	1,580,926	52,120	Feb 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 03 '26	Sale	231.02	3,594	830,279	178,081	Feb 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 03 '26	Sale	230.77	435	100,384	263,161	Feb 04 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 03 '26	Sale	230.77	1,334	307,845	223,813	Feb 04 09:05 PM
MICHAEL BROPHY	Officer	Feb 03 '26	Proposed Sale	231.10	5,671	1,310,568		Feb 03 04:32 PM
STEVEN L CHAPMAN	Officer	Feb 02 '26	Proposed Sale	230.72	85,299	19,679,799		Feb 02 04:58 PM
SOLOMON MOSHKEVICH	Officer	Feb 02 '26	Proposed Sale	231.44	3,000	694,309		Feb 02 04:12 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 28 '26	Sale	237.66	3,648	866,992	213,180	Jan 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 27 '26	Sale	240.53	2,322	558,514	216,828	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 28 '26	Sale	237.56	2,413	573,221	60,926	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	230.40	1,867	430,156	59,059	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '26	Sale	240.53	784	188,577	63,339	Jan 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 27 '26	Sale	240.53	291	69,995	263,787	Jan 29 08:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 28 '26	Sale	237.66	191	45,394	263,596	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 28 '26	Sale	237.66	1,000	237,662	225,147	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 27 '26	Sale	240.53	886	213,111	226,147	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 28 '26	Sale	237.66	1,200	285,195	142,486	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 27 '26	Sale	240.53	1,013	243,658	143,686	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 28 '26	Sale	237.66	928	220,551	175,540	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 27 '26	Sale	240.53	784	188,577	176,468	Jan 29 08:35 PM
MICHAEL BROPHY	Officer	Jan 29 '26	Proposed Sale	235.93	1,867	440,481		Jan 29 04:10 PM
MICHAEL BROPHY	Officer	Jan 28 '26	Proposed Sale	240.34	1,176	282,640		Jan 28 04:19 PM
Sheena Jonathan	CO-FOUNDER	Jan 23 '26	Sale	243.94	1,500	365,914	21,782	Jan 27 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 20 '26	Sale	234.74	71,932	16,885,203	217,354	Jan 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 21 '26	Sale	235.00	1,590	373,650	219,150	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 21 '26	Sale	242.54	37,175	9,016,585	64,123	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 20 '26	Sale	234.74	23,948	5,621,515	99,776	Jan 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 21 '26	Sale	234.46	3,163	741,612	264,078	Jan 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 20 '26	Sale	234.74	2,981	699,755	267,050	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 20 '26	Sale	234.74	19,234	4,514,958	226,615	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 21 '26	Sale	235.00	438	102,930	227,033	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 20 '26	Sale	234.74	23,205	5,447,105	144,992	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 21 '26	Sale	235.00	293	68,855	144,699	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 20 '26	Sale	234.74	17,806	4,179,752	177,591	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 21 '26	Sale	235.00	339	79,665	177,252	Jan 22 09:05 PM
MICHAEL BROPHY	Officer	Jan 21 '26	Proposed Sale	234.85	36,573	8,589,169		Jan 21 04:54 PM
Sheena Jonathan	CO-FOUNDER	Jan 05 '26	Option Exercise	9.59	39,615	379,908	262,581	Jan 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 02 '26	Sale	228.95	2,951	675,621	123,499	Jan 06 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 02 '26	Sale	229.08	3,848	881,482	136,568	Jan 06 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jan 02 '26	Proposed Sale	228.95	2,951	675,621		Jan 02 04:13 PM
STEVEN L CHAPMAN	Officer	Jan 02 '26	Proposed Sale	229.08	3,848	881,482		Jan 02 04:13 PM
Sheena Jonathan	CO-FOUNDER	Dec 19 '25	Sale	225.94	1,500	338,914	22,532	Dec 22 08:05 PM
Sheena Jonathan	Director	Dec 19 '25	Proposed Sale	220.00	4,500	990,000		Dec 19 10:03 AM
Sheena Jonathan	CO-FOUNDER	Dec 17 '25	Sale	227.01	3,070	696,912	222,966	Dec 17 08:35 PM
Sheena Jonathan	Director	Dec 17 '25	Proposed Sale	228.00	9,210	2,099,880		Dec 17 11:44 AM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Option Exercise	9.59	22,376	214,586	126,565	Dec 16 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Sale	230.76	4,692	1,082,714	113,065	Dec 16 09:05 PM
ROSENMAN HERM	Director	Dec 12 '25	Sale	227.42	48,419	11,011,477	20,342	Dec 16 09:05 PM
SOLOMON MOSHKEVICH	Officer	Dec 12 '25	Proposed Sale	230.76	4,692	1,082,714		Dec 12 05:17 PM
Herm Rosenman Trust	Board member	Dec 12 '25	Proposed Sale	233.13	48,419	11,287,921		Dec 12 10:07 AM
Sheena Jonathan	CO-FOUNDER	Dec 09 '25	Option Exercise	9.29	4,436	41,210	227,096	Dec 11 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Option Exercise	32.15	4,000	128,600	10,143	Dec 09 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Sale	243.10	4,366	1,061,389	5,777	Dec 09 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 04 '25	Option Exercise	19.68	6,902	135,831	208,601	Dec 08 09:55 PM
ROWAN EMMA CHAPMAN	Director	Dec 05 '25	Proposed Sale	243.10	4,366	1,061,391		Dec 05 07:25 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 01 '25	Sale	238.15	3,000	714,459	109,061	Dec 03 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 01 '25	Sale	238.07	4,400	1,047,502	140,416	Dec 03 08:35 PM
STEVEN L CHAPMAN	Officer	Dec 01 '25	Proposed Sale	238.07	4,400	1,047,501		Dec 01 04:10 PM
SOLOMON MOSHKEVICH	Officer	Dec 01 '25	Proposed Sale	238.15	3,000	714,459		Dec 01 04:08 PM
BOTHA ROELOF	Director	Nov 24 '25	Sale	236.12	75,000	17,708,936	1,154,198	Nov 26 05:00 PM
BV369 TRUST	Affiliate	Nov 24 '25	Proposed Sale	236.12	75,000	17,709,000		Nov 24 04:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM

Open in Screener

DGX

Quest Diagnostics, Inc

Apr 02 • 04:00PM ET

198.02

+0.33 0.17 %

Healthcare • Diagnostics & Research • USA • NYSE

DGX Quest Diagnostics, Inc daily Stock Chart

Peers: LH NEO EXAS OPK NTRA PMD

| Held by: VTI VOO VO IVV SPY VTV RSP XLV VOE VIG

Index	S&P 500	P/E	22.60	EPS (ttm)	8.76	Insider Own	0.49%	Shs Outstand	110.00M	Perf Week	-0.07%
Market Cap	21.76B	Forward P/E	17.26	EPS next Y	11.47	Insider Trans	-19.16%	Shs Float	109.33M	Perf Month	-5.00%
Enterprise Value	27.83B	PEG	2.09	EPS next Q	2.37	Inst Own	98.42%	Short Float	3.54%	Perf Quarter	14.11%
Income	988.00M	P/S	1.97	EPS this Y	7.98%	Inst Trans	-0.14%	Short Ratio	3.90	Perf Half Y	8.76%
Sales	11.04B	P/B	3.04	EPS next Y	7.86%	ROA	6.10%	Short Interest	3.87M	Perf YTD	14.11%
Book/sh	65.18	P/C	51.80	EPS next 5Y	8.25%	ROE	14.17%	52W High	213.50 -7.25%	Perf Year	17.90%
Cash/sh	3.82	P/FCF	16.01	EPS past 3/5Y	3.08% -3.64%	ROIC	7.67%	52W Low	157.20 25.97%	Perf 3Y	39.96%
Dividend Est.	3.27 (1.65%)	EV/EBITDA	12.81	Sales past 3/5Y	3.74% 3.18%	Gross Margin	31.93%	Volatility	2.16% 2.24%	Perf 5Y	52.98%
Dividend TTM	3.20 (1.62%)	EV/Sales	2.52	EPS Y/Y TTM	13.81%	Oper. Margin	14.53%	ATR (14)	4.41	Perf 10Y	172.87%
Dividend Ex-Date	Apr 06, 2026	Quick Ratio	0.96	Sales Y/Y TTM	11.78%	Profit Margin	8.95%	RSI (14)	49.65	Recom	2.18
Dividend Gr. 3/5Y	6.62% 7.39%	Current Ratio	1.04	EPS Q/Q	12.36%	SMA20	0.12%	Beta	0.66	Target Price	219.31
Payout	36.60%	Debt/Eq	0.89	Sales Q/Q	7.06%	SMA50	0.08%	Rel Volume	0.52	Prev Close	197.69
Employees	57000	LT Debt/Eq	0.80	Earnings	Apr 21 BMO	SMA200	7.42%	Avg Volume	991.80K	Price	198.02
IPO	Dec 17, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.42% 1.88%	Trades		Volume	520,129	Change	0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	Barclays	Equal Weight → Overweight	$210
Aug-25-25	Downgrade	Robert W. Baird	Outperform → Neutral	$194
Apr-02-25	Initiated	Redburn Atlantic	Buy	$195
Mar-04-25	Downgrade	Citigroup	Buy → Neutral	$185
Jan-06-25	Upgrade	Leerink Partners	Market Perform → Outperform	$169 → $174
Dec-17-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$145 → $172
Dec-10-24	Resumed	Jefferies	Buy	$175 → $185
Oct-23-24	Upgrade	Robert W. Baird	Neutral → Outperform	$157 → $182
Aug-28-24	Resumed	Evercore ISI	In-line	$165
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$145 → $165
Feb-26-24	Initiated	Leerink Partners	Market Perform	$135
Feb-07-24	Upgrade	Jefferies	Hold → Buy	$140 → $155
Jan-03-24	Initiated	Barclays	Equal Weight	$145
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy	$140 → $160
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral	$166 → $148
Apr-03-23	Upgrade	Citigroup	Sell → Neutral	$125 → $142
Jan-23-23	Initiated	Evercore ISI	In-line	$159
Nov-17-22	Downgrade	Citigroup	Neutral → Sell	$145 → $125
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight	$142

Show Previous Ratings

Apr-01-26 10:10AM	Digi Power X advances AI infrastructure strategy during 2025 (Proactive)
Mar-19-26 10:00AM	Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026 (PR Newswire)
Mar-12-26 04:07PM	Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors (PR Newswire)
Mar-10-26 08:24AM	Should You Continue to Hold DGX Stock in Your Portfolio? (Zacks)
Mar-05-26 02:53PM	Implied Volatility Surging for Quest Diagnostics Stock Options (Zacks)
08:10PM	Loading…
Mar-03-26 08:10PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
Mar-02-26 09:02AM	Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results (PR Newswire)
Feb-26-26 09:50AM	Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term (Zacks)
08:24AM	Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer (PR Newswire)
Feb-25-26 10:00AM	Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference (PR Newswire)
Feb-24-26 11:31PM	Labcorp expands PathAI pact to roll out digital pathology platform in US (MedTech Dive)
09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
Feb-18-26 06:38AM	Do Wall Street Analysts Like Quest Diagnostics Stock? (Barchart)
Feb-17-26 12:32AM	5 Insightful Analyst Questions From Quest's Q4 Earnings Call (StockStory)
Feb-11-26 09:15AM	Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? (Zacks)
12:32AM	Loading…
12:32AM	DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds (StockStory)
Feb-10-26 10:07PM	Quest Diagnostics Q4 Earnings Call Highlights (MarketBeat) +7.37%
05:45PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
05:08PM	Quest Diagnostics CEO: Chronic Care Disease Management a Big Driver (Bloomberg)
04:02PM	Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
03:30PM	Why Is Quest (DGX) Stock Soaring Today (StockStory)
02:54PM	Stock Market Today: Dow Weakens After Hitting A High; Medical Name Breaks Out (Live Coverage) (Investor's Business Daily)
02:05PM	Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike (Benzinga)
10:43AM	Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up (Zacks)
09:50AM	Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock (Zacks)
07:55AM	Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates (Zacks)
07:13AM	Quest Diagnostics Guides FY26 Above Estimates; Boosts Dividend 7.5% - Update (RTT News)
07:06AM	Quest Diagnostics: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue (StockStory)
06:47AM	Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share (PR Newswire)
06:33AM	Loading…
06:33AM	Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization (PR Newswire)
Feb-09-26 02:08PM	MedTech Stocks to Report Earnings on Feb. 10: DGX, ZBH & EW (Zacks)
Feb-08-26 10:04PM	Quest (DGX) Q4 Earnings: What To Expect (StockStory)
Feb-06-26 09:45AM	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
Feb-04-26 09:40AM	Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-03-26 10:23AM	DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand (Zacks)
Feb-02-26 08:52AM	Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease (PR Newswire)
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-26-26 09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-21-26 02:35PM	Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year (PR Newswire)
Jan-15-26 11:15PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
09:00AM	Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect (PR Newswire)
Jan-13-26 11:06PM	3 Reasons to Sell DGX and 1 Stock to Buy Instead (StockStory)
Jan-12-26 09:40AM	Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term (Zacks)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
09:08AM	Is it the Right Time to Add STERIS Stock to Your Portfolio? (Zacks)
07:45AM	Tempus AI Stock Surges 82.4% in a Year: What's Driving It? (Zacks)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
10:00AM	Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 (PR Newswire)
08:27AM	Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now? (Zacks)
07:57AM	Is This the Right Time to Add Resmed Stock to Your Portfolio? (Zacks)
Jan-07-26 09:45AM	Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
07:35AM	Here's Why You Should Add NVST Stock to Your Portfolio Right Now (Zacks)
07:25AM	IDEXX Stock Up 64.7% in a Year: What's Driving the Growth? (Zacks)
Jan-06-26 10:01AM	Data Featuring Haystack MRD from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:17AM	Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead? (Zacks)
08:12AM	Should Labcorp Stock Stay in Your Portfolio Right Now? (Zacks)
Jan-05-26 08:58AM	Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan (PR Newswire)
06:51AM	What You Need To Know Ahead of Quest Diagnostics' Earnings Release (Barchart)
Jan-02-26 07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Jan-01-26 10:33PM	Q3 Earnings Highlights: Quest (NYSE:DGX) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Dec-30-25 12:00PM	Quest Diagnostics (DGX) Upgraded to Buy: Here's Why (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 09:40AM	Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-19-25 03:20PM	Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-18-25 07:14PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
07:54AM	How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Dec-17-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-15-25 08:07AM	Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector? (Barchart)
Dec-12-25 09:45AM	Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock (Zacks)
Dec-03-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Dec-01-25 09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
08:30AM	Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave Multiple Sclerosis Disease Activity (MSDA) Test Across the United States (Business Wire)
Nov-28-25 11:30AM	Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Chemed (CHE) Down 5.2% Since Last Earnings Report: Can It Rebound? (Zacks)
08:23AM	HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet? (Zacks)
Nov-26-25 09:45AM	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
Nov-24-25 07:53AM	Should You Hold Quest Diagnostics Stock in Your Portfolio for Now? (Zacks)
Nov-20-25 11:30AM	Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue? (Zacks)
07:08AM	Quest Diagnostics Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
Nov-14-25 06:16AM	Labcorp inks deal to buy Parkview Health outreach laboratory assets (MedTech Dive)
Nov-13-25 11:49AM	Hims & Hers Bets on Lab Testing to Boost Growth (The Wall Street Journal)
09:40AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
Nov-11-25 07:50PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
04:22PM	Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire)
Nov-10-25 09:45AM	Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Nov-03-25 04:09PM	Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference (PR Newswire)
Oct-29-25 07:09PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
Oct-27-25 09:40AM	Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term (Zacks)
07:45AM	New Study Demonstrates Accuracy of Two Quest AD-Detect Tests for Alzheimer's Disease Diagnosis (PR Newswire)
Oct-22-25 05:36PM	Quest Diagnostics Incorporated (DGX): A Bull Case Theory (Insider Monkey)
09:45AM	Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock (Zacks)
Oct-21-25 03:07PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
03:02PM	Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:29AM	Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise (Zacks)
07:55AM	Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:59AM	Quest (NYSE:DGX) Posts Better-Than-Expected Sales In Q3 (StockStory)

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to physicians, hospitals, patients, and consumers. The All Other segment consists of risk assessment services and healthcare information technology. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doherty Catherine T.	EVP, Regional Businesses	Mar 05 '26	Sale	206.21	5,558	1,146,115	67,122	Mar 06 04:45 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Mar 05 '26	Sale	206.21	3,878	799,682	37,557	Mar 06 04:44 PM
Plewman Patrick	SVP for Diagnostic Services	Mar 05 '26	Sale	206.21	2,855	588,730	15,198	Mar 06 04:44 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Mar 04 '26	Sale	204.86	2,628	538,372	13,441	Mar 06 04:43 PM
PREVOZNIK MICHAEL E	Officer	Mar 05 '26	Proposed Sale	206.21	3,878	799,682		Mar 05 11:53 AM
Doherty Catherine T.	Officer	Mar 05 '26	Proposed Sale	206.21	5,558	1,146,115		Mar 05 10:55 AM
Plewman Patrick	Officer	Mar 05 '26	Proposed Sale	206.21	2,855	588,730		Mar 05 10:43 AM
Doherty Catherine T.	EVP, Regional Businesses	Mar 03 '26	Sale	207.73	632	131,285	67,122	Mar 04 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Mar 03 '26	Sale	207.73	526	109,266	37,557	Mar 04 04:38 PM
Davis J. E.	CEO and President	Mar 02 '26	Sale	212.52	10,000	2,125,200	117,185	Mar 04 04:38 PM
Plewman Patrick	SVP for Diagnostic Services	Mar 03 '26	Sale	207.73	410	85,169	15,198	Mar 04 04:38 PM
Doherty Catherine T.	Officer	Mar 03 '26	Proposed Sale	207.73	632	131,285		Mar 03 12:53 PM
PREVOZNIK MICHAEL E	Officer	Mar 03 '26	Proposed Sale	207.73	526	109,266		Mar 03 12:12 PM
Plewman Patrick	Officer	Mar 03 '26	Proposed Sale	207.73	410	85,169		Mar 03 11:52 AM
Davis J. E.	Officer	Mar 02 '26	Proposed Sale	212.52	10,000	2,125,200		Mar 02 02:21 PM
Plewman Patrick	SVP for Diagnostic Services	Feb 19 '26	Sale	204.83	958	196,227	15,838	Feb 20 05:13 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 19 '26	Sale	204.83	1,111	227,566	38,371	Feb 20 05:12 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 19 '26	Sale	204.83	1,433	293,521	68,402	Feb 20 05:11 PM
Plewman Patrick	Officer	Feb 19 '26	Proposed Sale	204.83	958	196,227		Feb 19 10:34 AM
Doherty Catherine T.	Officer	Feb 19 '26	Proposed Sale	204.83	1,433	293,521		Feb 19 10:23 AM
PREVOZNIK MICHAEL E	Officer	Feb 19 '26	Proposed Sale	204.83	1,111	227,566		Feb 19 10:19 AM
Doherty Catherine T.	EVP, Regional Businesses	Feb 13 '26	Option Exercise	112.17	26,165	2,934,928	94,233	Feb 17 04:37 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 13 '26	Sale	206.15	26,165	5,393,815	68,068	Feb 17 04:37 PM
Doherty Catherine T.	Officer	Feb 13 '26	Proposed Sale	207.48	26,165	5,428,714		Feb 13 10:42 AM
Plewman Patrick	SVP for Diagnostic Services	Feb 10 '26	Option Exercise	121.81	5,662	689,660	21,043	Feb 12 04:33 PM
Plewman Patrick	SVP for Diagnostic Services	Feb 10 '26	Sale	204.00	5,662	1,155,048	15,381	Feb 12 04:33 PM
Plewman Patrick	Officer	Feb 10 '26	Proposed Sale	204.00	5,662	1,155,048		Feb 10 12:46 PM
Davis J. E.	CEO and President	Nov 25 '25	Option Exercise	95.80	55,093	5,277,634	175,573	Nov 28 04:30 PM
Davis J. E.	CEO and President	Nov 25 '25	Sale	192.22	55,093	10,589,760	120,480	Nov 28 04:30 PM
Gregg Vicky B	Director	Nov 25 '25	Sale	191.76	1,250	239,700	17,037	Nov 28 04:30 PM
Davis J. E.	Officer	Nov 25 '25	Proposed Sale	192.22	55,093	10,589,762		Nov 25 04:24 PM
Gregg Vicky B	Director	Nov 25 '25	Proposed Sale	191.76	1,250	239,700		Nov 25 09:42 AM
DELANEY MARK E	SVP & Chief Commercial Officer	Nov 18 '25	Option Exercise	144.46	7,946	1,147,845	15,476	Nov 20 04:28 PM
DELANEY MARK E	SVP & Chief Commercial Officer	Nov 18 '25	Sale	187.35	7,946	1,488,683	7,530	Nov 20 04:28 PM
DELANEY MARK E	Officer	Nov 18 '25	Proposed Sale	187.35	7,946	1,488,683		Nov 18 11:02 AM
PFEIFFER GARY M	Director	Oct 22 '25	Sale	182.40	1,482	270,317	29,431	Oct 24 06:10 PM
PFEIFFER GARY M	Director	Oct 22 '25	Proposed Sale	182.40	1,482	270,317		Oct 22 02:10 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 26 '25	Option Exercise	103.57	227	23,510	38,344	Sep 30 04:36 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 26 '25	Sale	188.13	227	42,706	38,117	Sep 30 04:36 PM
PREVOZNIK MICHAEL E	Officer	Sep 26 '25	Proposed Sale	188.13	227	42,706		Sep 26 04:12 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 23 '25	Option Exercise	103.57	28,288	2,929,788	66,405	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 24 '25	Option Exercise	103.57	175	18,125	38,292	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 23 '25	Sale	187.12	28,288	5,293,313	38,117	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Sep 24 '25	Sale	187.02	175	32,729	38,117	Sep 25 04:39 PM
PREVOZNIK MICHAEL E	Officer	Sep 24 '25	Proposed Sale	187.02	175	32,729		Sep 24 04:10 PM
PREVOZNIK MICHAEL E	Officer	Sep 23 '25	Proposed Sale	187.12	28,288	5,293,313		Sep 23 04:14 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 21 '25	Sale	185.00	1,975	365,375	15,269	Aug 25 04:27 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 19 '25	Option Exercise	112.17	4,532	508,354	21,776	Aug 21 04:34 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 19 '25	Sale	183.00	4,532	829,356	17,244	Aug 21 04:34 PM
Plewman Patrick	Officer	Aug 21 '25	Proposed Sale	185.00	1,975	365,375		Aug 21 12:10 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 15 '25	Sale	180.00	1,975	355,500	17,244	Aug 19 04:47 PM
Plewman Patrick	Director	Aug 19 '25	Proposed Sale	183.00	4,532	829,356		Aug 19 04:09 PM
Plewman Patrick	Officer	Aug 15 '25	Proposed Sale	180.00	72	12,960		Aug 15 05:29 PM
Plewman Patrick	Officer	Aug 15 '25	Proposed Sale	180.00	1,903	342,540		Aug 15 05:22 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 06 '25	Option Exercise	86.63	3,560	308,403	24,745	Aug 08 04:40 PM
Plewman Patrick	SVP for Diagnostic Services	Aug 06 '25	Sale	175.00	5,535	968,625	19,219	Aug 08 04:40 PM
Plewman Patrick	Officer	Aug 06 '25	Proposed Sale	175.00	5,535	968,625		Aug 06 01:54 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 30 '25	Option Exercise	102.77	8,269	849,764	15,884	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 30 '25	Sale	167.40	8,269	1,384,231	10,660	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Jul 31 '25	Sale	170.00	2,210	375,700	8,450	Aug 01 04:37 PM
KUPPUSAMY KARTHIK	Officer	Jul 31 '25	Proposed Sale	170.00	2,210	375,700		Jul 31 02:27 PM
KUPPUSAMY KARTHIK	Officer	Jul 30 '25	Proposed Sale	167.40	8,269	1,384,231		Jul 30 03:59 PM
DELANEY MARK E	SVP & Chief Commercial Officer	May 12 '25	Sale	175.72	874	153,579	8,372	May 14 05:12 PM
DELANEY MARK E	SVP & Chief Commercial Officer	May 13 '25	Sale	175.31	874	153,221	7,498	May 14 05:12 PM
DELANEY MARK E	Officer	May 13 '25	Proposed Sale	175.31	874	153,221		May 13 09:59 AM
DELANEY MARK E	Officer	May 12 '25	Proposed Sale	175.72	874	153,579		May 12 10:01 AM

Open in Screener

CELC

Celcuity Inc

Apr 02 • 04:00PM ET

112.63

-0.30 -0.27 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ACAD NBIX BIIB BMRN EXEL ALKS INCY BHVN IONS

| Held by: VTI XBI IWM VXF IWO SCHA VTWO IWC VHT CANC

Index	RUT	P/E	-	EPS (ttm)	-3.79	Insider Own	21.77%	Shs Outstand	48.24M	Perf Week	-1.90%
Market Cap	5.44B	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-0.44%	Shs Float	37.81M	Perf Month	0.40%
Enterprise Value	5.32B	PEG	-	EPS next Q	-1.04	Inst Own	91.51%	Short Float	24.14%	Perf Quarter	12.92%
Income	-177.04M	P/S	-	EPS this Y	-3.24%	Inst Trans	7.58%	Short Ratio	12.53	Perf Half Y	149.07%
Sales	0.00M	P/B	54.04	EPS next Y	96.11%	ROA	-49.75%	Short Interest	9.13M	Perf YTD	12.92%
Book/sh	2.08	P/C	12.33	EPS next 5Y	-	ROE	-163.80%	52W High	120.32 -6.39%	Perf Year	1103.31%
Cash/sh	9.13	P/FCF	-	EPS past 3/5Y	-13.08% -32.62%	ROIC	-41.91%	52W Low	7.57 1386.86%	Perf 3Y	998.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.64% 5.75%	Perf 5Y	663.59%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-34.71%	Oper. Margin	-	ATR (14)	6.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.64	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	10.55	EPS Q/Q	-13.49%	SMA20	0.80%	Beta	0.09	Target Price	128.60
Payout	-	Debt/Eq	3.20	Sales Q/Q	-	SMA50	2.42%	Rel Volume	0.69	Prev Close	112.93
Employees	155	LT Debt/Eq	3.20	Earnings	Mar 25 AMC	SMA200	52.12%	Avg Volume	728.53K	Price	112.63
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.92% -	Trades		Volume	501,432	Change	-0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Wells Fargo	Overweight	$126
Nov-18-25	Initiated	Wolfe Research	Outperform	$110
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-22-25	Initiated	Guggenheim	Buy	$110
Jul-01-25	Resumed	Stifel	Buy	$30
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Mar-26-26 08:30AM	Celcuity Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-25-26 11:02PM	Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... (GuruFocus.com) +8.05%
04:01PM	Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-26 08:00AM	Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-09-26 05:42PM	Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology (GlobeNewswire)
09:04PM	Loading…
Mar-07-26 09:04PM	Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference (MarketBeat)
Feb-25-26 04:01PM	Celcuity To Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-26 09:40AM	Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-12-26 04:05PM	Celcuity Appoints Charles Romp to its Board of Directors (GlobeNewswire)
Feb-11-26 11:42PM	Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference (MarketBeat)
Feb-04-26 07:05AM	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 09:33AM	Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances (Insider Monkey)
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-20-26 07:30AM	Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
Jan-11-26 12:59AM	Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) (Insider Monkey)
11:47AM	Loading…
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-11-25 08:24PM	Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank (Zacks)
02:35PM	Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-25 04:43PM	3 Stocks You'll Wish You Bought Before 2026 (MarketBeat) +5.87%
Nov-26-25 04:05PM	Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
07:05AM	Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-23-25 07:02AM	Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View (Insider Monkey)
Nov-18-25 09:35AM	Block upgraded, Dell downgraded: Wall Streets top analyst calls (TipRanks)
Nov-17-25 04:05PM	Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (GlobeNewswire)
09:34AM	Block upgraded, Dell downgraded: Wall Street's top analyst calls (The Fly)
Nov-13-25 12:01AM	Celcuity Inc (CELC) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-12-25 04:01PM	Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.56%
Nov-06-25 10:08AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. (Investor's Business Daily)
10:03AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year. (Investor's Business Daily)
07:05AM	Loading…
Nov-05-25 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-04-25 07:05AM	Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-03-25 05:22AM	ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer (Clinical Trials Arena)
Oct-21-25 12:55PM	Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result (Insider Monkey) -7.20%
Oct-20-25 04:13PM	Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily) +35.84%
10:02AM	Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily)
Oct-18-25 04:30AM	Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:30AM	Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial (GlobeNewswire)
04:30AM	Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") (GlobeNewswire)
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire)
Sep-30-25 12:47PM	Celcuity Inc. (CELC)'s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review (Insider Monkey) -5.13%
Sep-22-25 09:15AM	Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Sep-09-25 04:01PM	Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance (GlobeNewswire) -7.96%
Aug-27-25 04:05PM	Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program (GlobeNewswire) +9.29%
Aug-15-25 03:24AM	Celcuity Inc (CELC) Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances (GuruFocus.com)
Aug-14-25 04:01PM	Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-30-25 06:30AM	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire)
02:15PM	Up 215% YTD, Should You Grab This Growth Stock Before Its Too Late? (Barchart)
09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
09:43AM	Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial (Insider Monkey)
Jul-28-25 04:02PM	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +167.18%
02:09PM	Celcuity stock rallies on Phase III breast cancer trial progress (Clinical Trials Arena)
11:55AM	Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More (Investopedia)
10:09AM	Celcuity Stock Triples on Positive Breast Cancer Treatment Study (Investopedia)
09:42AM	Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer (Benzinga)
08:15AM	Celcuity shares triple on late-stage results for breast cancer therapy (BioPharma Dive)
07:00AM	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial (GlobeNewswire)
Jul-25-25 04:05PM	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-24-25 04:01PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-14-25 07:05AM	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 (GlobeNewswire)
Jun-30-25 07:05AM	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib (GlobeNewswire) +6.46%
May-21-25 07:05AM	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences (GlobeNewswire)
May-15-25 09:56AM	Q1 2025 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Celcuity Inc (CELC) Q1 2025 Earnings Call Highlights: Navigating Increased Losses and Strategic ... (GuruFocus.com)
May-14-25 04:01PM	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Apr-01-25 08:41AM	Q4 2024 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
03:03AM	Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 10:50PM	Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:05AM	Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences (GlobeNewswire) -8.99%
Dec-11-24 07:05AM	Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-15-24 02:20AM	Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges (GuruFocus.com) -10.28%
Nov-14-24 04:01PM	Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 07:05AM	Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire)
Nov-07-24 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Oct-09-24 06:26PM	Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses (GuruFocus.com) -5.83%
Oct-07-24 09:10PM	Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings (GuruFocus.com)
Sep-10-24 09:55AM	Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-20-24 12:00PM	Celcuity (CELC) Upgraded to Buy: Here's Why (Zacks)
Aug-14-24 04:01PM	Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jun-03-24 04:01PM	Celcuity To Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -5.25%
May-30-24 07:36AM	Celcuity Announces Pricing of Underwritten Common Stock Offering (GlobeNewswire)
07:00AM	Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing (GlobeNewswire)
May-16-24 11:54AM	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating (MT Newswires)
03:08AM	Celcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
May-15-24 08:55PM	CELC Stock Earnings: Celcuity Beats EPS for Q1 2024 (InvestorPlace)
06:04PM	Celcuity Q1 Net Loss Widens; Shares Rise After Hours (MT Newswires)
04:01PM	Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buller Richard E	Director	Mar 31 '26	Option Exercise	5.10	3,000	15,300	9,760	Apr 02 04:05 PM
Buller Richard E	Director	Mar 31 '26	Sale	110.27	3,000	330,804	6,760	Apr 02 04:05 PM
Buller Richard E	Director	Mar 31 '26	Proposed Sale	110.27	6,000	661,607		Mar 31 04:38 PM
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29 04:31 PM
Dalvey David	Director	Jan 27 '26	Proposed Sale	120.03	20,000	2,400,538		Jan 27 12:21 PM
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09 04:23 PM
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,070	6,760	Dec 09 04:23 PM
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08 04:30 PM
Buller Richard E	Director	Dec 05 '25	Proposed Sale	105.68	3,000	317,040		Dec 05 05:31 PM
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03 04:09 PM
Buller Richard E	Director	Dec 01 '25	Proposed Sale	98.13	1,100	107,943		Dec 01 05:46 PM
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,016	110,000	Nov 24 04:07 PM
Buller Richard E	Director	Nov 20 '25	Option Exercise	14.83	3,900	57,837	11,160	Nov 21 04:14 PM
Buller Richard E	Director	Nov 20 '25	Sale	96.73	3,900	377,255	7,260	Nov 21 04:14 PM
Dalvey David	Director	Nov 21 '25	Proposed Sale	100.00	15,000	1,500,016		Nov 21 01:41 PM
Buller Richard E	Director	Nov 20 '25	Proposed Sale	96.73	3,900	377,255		Nov 20 04:33 PM
BAKER BROS. ADVISORS LP	10% Owner	Sep 08 '25	Buy	56.27	170,100	9,571,319	7,211,484	Sep 10 04:06 PM
Dalvey David	Director	Jul 28 '25	Sale	43.98	100,000	4,397,603	125,000	Jul 30 04:15 PM
Dalvey David	Director	Jul 28 '25	Sale	45.12	9,325	420,767	0	Jul 30 04:15 PM
Brightstone Venture Capital Fu	Director	Jul 28 '25	Proposed Sale	43.98	100,000	4,397,605		Jul 28 02:52 PM
Dalvey David	Director	Jul 28 '25	Proposed Sale	45.12	9,325	420,766		Jul 28 02:00 PM

Open in Screener

RDNT

Radnet Inc

Apr 02 • 04:00PM ET

54.79

-0.52 -0.94 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: HCA DVA THC UHS AMED ACHC CYH USPH MD ADUS

| Held by: IJR VTI VB IWM VBK VXF SPSM QTUM IWO VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.26	Insider Own	10.27%	Shs Outstand	77.40M	Perf Week	-7.78%
Market Cap	4.25B	Forward P/E	54.25	EPS next Y	1.01	Insider Trans	-1.55%	Shs Float	69.64M	Perf Month	-23.19%
Enterprise Value	5.61B	PEG	1.22	EPS next Q	-0.15	Inst Own	98.42%	Short Float	11.93%	Perf Quarter	-23.21%
Income	-18.65M	P/S	2.08	EPS this Y	61.97%	Inst Trans	0.33%	Short Ratio	10.24	Perf Half Y	-29.75%
Sales	2.04B	P/B	3.89	EPS next Y	59.89%	ROA	-0.50%	Short Interest	8.31M	Perf YTD	-23.21%
Book/sh	14.08	P/C	5.54	EPS next 5Y	44.63%	ROE	-1.87%	52W High	85.84 -36.17%	Perf Year	4.34%
Cash/sh	9.89	P/FCF	49.69	EPS past 3/5Y	- 3.18%	ROIC	-0.65%	52W Low	45.00 21.75%	Perf 3Y	118.90%
Dividend Est.	-	EV/EBITDA	23.09	Sales past 3/5Y	12.57% 13.74%	Gross Margin	4.45%	Volatility	4.50% 5.17%	Perf 5Y	148.82%
Dividend TTM	-	EV/Sales	2.75	EPS Y/Y TTM	-807.87%	Oper. Margin	4.45%	ATR (14)	3.00	Perf 10Y	1022.75%
Dividend Ex-Date	-	Quick Ratio	1.76	Sales Y/Y TTM	11.51%	Profit Margin	-0.91%	RSI (14)	31.02	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	1.76	EPS Q/Q	-111.02%	SMA20	-8.71%	Beta	1.56	Target Price	92.38
Payout	-	Debt/Eq	1.71	Sales Q/Q	14.80%	SMA50	-17.21%	Rel Volume	1.23	Prev Close	55.31
Employees	8844	LT Debt/Eq	1.63	Earnings	Mar 02 BMO	SMA200	-21.05%	Avg Volume	811.23K	Price	54.79
IPO	Feb 27, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.58% 6.00%	Trades		Volume	1,000,797	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Initiated	KeyBanc Capital Markets	Overweight	$92
Jun-13-25	Initiated	B. Riley Securities	Buy	$69
Mar-05-25	Upgrade	Raymond James	Outperform → Strong Buy	$85 → $65
Sep-06-24	Upgrade	Barclays	Equal Weight → Overweight	$57 → $79
Mar-06-24	Initiated	Barclays	Equal Weight	$48
Aug-31-23	Initiated	Truist	Buy	$40
Mar-31-23	Initiated	CJS Securities	Market Outperform	$30
Mar-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$30
Aug-12-21	Initiated	Barclays	Overweight	$39
Mar-15-19	Downgrade	Raymond James	Strong Buy → Outperform	$16 → $17.50
Mar-14-18	Initiated	Raymond James	Strong Buy
Aug-22-17	Upgrade	Jefferies	Hold → Buy
Jun-02-16	Initiated	Sterne Agee CRT	Neutral
Apr-15-16	Initiated	Sidoti	Buy	$9
Mar-17-09	Reiterated	Jefferies & Co	Buy	$12 → $4
Oct-15-08	Initiated	RBC Capital Mkts	Sector Perform	$4
Jul-14-08	Upgrade	Stanford Research	Hold → Buy	$9
Apr-02-08	Upgrade	Morgan Keegan	Mkt Perform → Outperform
Mar-14-08	Downgrade	Morgan Keegan	Outperform → Mkt Perform
Dec-19-07	Initiated	Leerink Swann	Outperform

Show Previous Ratings

Mar-17-26 06:00AM	RadNet, Inc. to Present Today at the KeyBanc Capital Markets Healthcare Forum (GlobeNewswire)
Mar-11-26 04:15PM	RadNet, Inc. to Present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12th (GlobeNewswire)
Mar-04-26 07:00AM	DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026 (GlobeNewswire)
06:00AM	RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS (GlobeNewswire)
Mar-03-26 12:19PM	Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes (PR Newswire)
07:10AM	Loading…
07:10AM	RadNet bolsters clinical AI capabilities with Gleamer acquisition (Medical Device Network)
Mar-02-26 11:49PM	RadNet to acquire radiology AI company Gleamer (MedTech Dive) +7.75%
06:00PM	RadNet Inc (RDNT) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic AI Expansion (GuruFocus.com)
05:32PM	RadNet Q4 Earnings Call Highlights (MarketBeat)
04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart)
04:33PM	RadNet, Inc. Q4 2025 Earnings Call Summary (Moby)
04:17PM	RadNet's (NASDAQ:RDNT) Q4 CY2025: Strong Sales (StockStory)
01:16PM	RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026 (GlobeNewswire)
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart)
09:30AM	Compared to Estimates, RadNet (RDNT) Q4 Earnings: A Look at Key Metrics (Zacks)
08:31AM	Loading…
08:31AM	RadNet Makes $270 Million Bet On AI Future With Gleamer Buyout (Benzinga)
07:15AM	RadNet (RDNT) Q4 Earnings and Revenues Surpass Estimates (Zacks)
06:18AM	RadNet: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA?¹? and Releases 2026 Financial Guidance (GlobeNewswire)
05:45AM	RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide (GlobeNewswire)
Feb-26-26 04:01PM	DeepHealth Achieves CE Mark for TechLive and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution (GlobeNewswire)
Feb-25-26 09:15AM	Exploring Analyst Estimates for RadNet (RDNT) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-17-26 06:00AM	RadNet, Inc. Announces Date of its Fourth Quarter 2025 Financial Results Conference Call (GlobeNewswire)
Feb-03-26 06:00AM	RadNet Enters Indiana with Acquisition of Northwest Radiology (GlobeNewswire)
Jan-27-26 10:14AM	AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market (PR Newswire)
Jan-09-26 06:00AM	RadNet, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026 (GlobeNewswire)
Jan-07-26 06:15AM	RadNet Expands to Southwest Florida with Acquisition of Radiology Regional (GlobeNewswire)
06:00AM	RadNet Names Four Leaders to Expanded Executive Roles (GlobeNewswire)
Dec-22-25 11:03PM	3 Reasons RDNT is Risky and 1 Stock to Buy Instead (StockStory)
Dec-19-25 03:16PM	Why Is RadNet (RDNT) Stock Rocketing Higher Today (StockStory) +7.39%
01:09PM	Loading…
Dec-18-25 01:09PM	RadNet, Inc. (RDNT): A Bear Case Theory (Insider Monkey)
Dec-16-25 04:01PM	RadNet (RDNT) Stock Trades Down, Here Is Why (StockStory)
Dec-07-25 10:32PM	Q3 Earnings Highlights: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Dec-05-25 11:11AM	Why RadNet (RDNT) Shares Are Trading Lower Today (StockStory)
Dec-01-25 06:00AM	DeepHealth Launches Breast Suite, Elevating Breast Cancer Detection, Risk Stratification and Workflow (GlobeNewswire)
Nov-30-25 08:00AM	DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care (GlobeNewswire)
Nov-20-25 06:00AM	RadNet's DeepHealth Announces Wichita Radiological Group as First Operations Suite Customer (GlobeNewswire)
Nov-17-25 04:05PM	Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow (GlobeNewswire)
Nov-12-25 04:05PM	GE HealthCare and RadNet's DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging Across Multiple Modalities and Remote Scanning (GlobeNewswire) -5.16%
05:22AM	RadNet acquires healthcare management solutions provider CIMAR UK (Hospital Management)
Nov-11-25 06:00AM	RadNet Acquires CIMAR UK, Empowering DeepHealth to Accelerate AI-Powered Imaging, Reporting and Image-Based Screening (GlobeNewswire)
Nov-10-25 06:00PM	RadNet Inc (RDNT) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth in ... (GuruFocus.com)
09:30AM	RadNet (RDNT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:04AM	RadNet: Q3 Earnings Snapshot (Associated Press Finance)
Nov-09-25 04:10PM	RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges (GlobeNewswire)
Nov-07-25 10:00PM	RadNet Earnings: What To Look For From RDNT (StockStory)
Nov-06-25 09:15AM	Exploring Analyst Estimates for RadNet (RDNT) Q3 Earnings, Beyond Revenue and EPS (Zacks)
07:15AM	LifeStance Health Group (LFST) Reports Break-Even Earnings for Q3 (Zacks)
Nov-05-25 07:15PM	The Pennant Group, Inc. (PNTG) Tops Q3 Earnings and Revenue Estimates (Zacks)
06:00AM	RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT's Assets (GlobeNewswire)
Nov-04-25 07:12AM	RadNet (RDNT) Surged Following the Quarterly Results (Insider Monkey)
06:00AM	RadNet Announces the Agenda for its November 11, 2025 Investor Day (GlobeNewswire)
Oct-31-25 03:20AM	Zacks.com featured highlights include RadNet, Mission Produce, Castle Biosciences and FreightCar America (Zacks)
12:00AM	3 Reasons to Avoid RDNT and 1 Stock to Buy Instead (StockStory)
Oct-30-25 12:01PM	Forget Profit, Pick These 4 Stocks With Increasing Cash Flows (Zacks)
Oct-29-25 06:00PM	Encompass Health (EHC) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-28-25 05:35PM	Chemed (CHE) Lags Q3 Earnings and Revenue Estimates (Zacks)
Oct-23-25 08:30AM	Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market (PR Newswire)
Oct-21-25 06:00AM	RadNet to Host Investor Day on November 11, 2025 (GlobeNewswire)
Oct-20-25 06:00AM	RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call (GlobeNewswire)
Sep-26-25 06:00AM	RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025 (GlobeNewswire)
Sep-15-25 11:34PM	Q2 Earnings Highlights: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Sep-08-25 12:51PM	RadNet, Inc. to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025 (GlobeNewswire)
Sep-04-25 12:35AM	1 High-Flying Stock for Long-Term Investors and 2 We Avoid (StockStory)
Aug-26-25 08:54AM	$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms (PR Newswire)
Aug-17-25 01:30AM	5 Revealing Analyst Questions From RadNet's Q2 Earnings Call (StockStory)
Aug-13-25 12:16PM	RadNet (RDNT) Stock Trades Up, Here Is Why (StockStory) +7.56%
Aug-12-25 11:09AM	Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction (PR Newswire)
03:05AM	RadNet Inc (RDNT) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
Aug-11-25 09:30AM	RadNet (RDNT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +16.19%
05:15AM	RadNet: Q2 Earnings Snapshot (Associated Press Finance)
Aug-10-25 04:00PM	RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges (GlobeNewswire)
Aug-08-25 11:00PM	RadNet (RDNT) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory) +16.19%
09:19AM	Earnings To Watch: RadNet Inc (RDNT) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 07:15AM	LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive (GlobeNewswire)
Aug-06-25 09:15AM	Wall Street's Insights Into Key Metrics Ahead of RadNet (RDNT) Q2 Earnings (Zacks)
Jul-30-25 12:04AM	3 Reasons to Avoid RDNT and 1 Stock to Buy Instead (StockStory)
Jul-29-25 08:05AM	Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver? (Zacks)
Jul-25-25 06:00AM	RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call (GlobeNewswire)
Jul-21-25 04:49AM	RadNets DeepHealth concludes iCAD acquisition (Medical Device Network)
Jul-17-25 09:00AM	RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD (GlobeNewswire)
Jul-16-25 08:55AM	Hologic Rides on AI-Powered Breast Health Innovations: What's Next? (Zacks)
Jul-09-25 12:00PM	RadNet (RDNT) Stock Trades Up, Here Is Why (StockStory)
06:00AM	Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet's AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California (GlobeNewswire)
Jul-02-25 01:31AM	The 5 Most Interesting Analyst Questions From RadNet's Q1 Earnings Call (StockStory)
Jul-01-25 11:34PM	Q1 Earnings Highs And Lows: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks (StockStory)
Jun-17-25 10:18AM	AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers (PR Newswire)
Jun-11-25 04:55PM	RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives (GlobeNewswire)
Jun-05-25 07:37AM	RadNet acquires See-Mode to bolster AI ultrasound screening for thyroid cancer (Medical Device Network)
Jun-04-25 04:01PM	RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics (GlobeNewswire)
10:33AM	RDNT Q1 Earnings Call: Severe Weather Disruptions and Ongoing Shift to Advanced Imaging Highlight Results (StockStory)
May-26-25 11:46AM	What Makes RadNet (RDNT) an Investment Bet? (Insider Monkey)
May-13-25 11:28AM	Behind the FDA's AI Push: A Growing Class of Public Healthcare Innovators (PR Newswire) +6.14%
03:06AM	RadNet Inc (RDNT) Q1 2025 Earnings Call Highlights: Navigating Challenges and Seizing Growth ... (GuruFocus.com)
12:52AM	Q1 2025 RadNet Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:35AM	RadNet (RDNT) Fell on Lower Than Expected Guidance (Insider Monkey)
05:55AM	RadNet: Q1 Earnings Snapshot (Associated Press Finance)
May-11-25 04:00PM	RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹ (GlobeNewswire)
May-09-25 09:21AM	What To Expect From RadNet Inc (RDNT) Q1 2025 Earnings (GuruFocus.com)

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sorensen Alma Gregory	Chief Strategy Officer	Mar 19 '26	Sale	62.20	15,000	933,014	1,208,923	Mar 23 04:15 PM
ALMA GREGORY SORENSEN &KRISTII	Director	Mar 19 '26	Proposed Sale	62.20	15,000	933,006		Mar 19 04:50 PM
ALMA GREGORY SORENSEN	Director	Mar 16 '26	Proposed Sale	64.10	5,919	379,408		Mar 18 07:42 PM
Sorensen Alma Gregory	Chief Strategy Officer	Mar 18 '26	Sale	62.15	15,000	932,280	1,223,923	Mar 18 07:38 PM
ALMA GREGORY SORENSEN &KRISTII	Director	Mar 18 '26	Proposed Sale	62.15	15,000	932,259		Mar 18 04:22 PM
Sorensen Alma Gregory	Chief Strategy Officer	Mar 10 '26	Option Exercise	0.00	62,964	0	1,244,842	Mar 12 05:52 PM
STOLPER MARK	EVP, Chief Financial Officer	Dec 10 '25	Option Exercise	6.07	35,703	216,717	103,715	Dec 12 04:15 PM
Katz David Jeffrey	EVP and Chief Legal Officer	Dec 10 '25	Option Exercise	29.44	3,396	99,978	71,577	Dec 12 04:15 PM
Forthuber Stephen M	Pres & COO-Eastern Operations	Dec 05 '25	Sale	78.33	45,088	3,531,849	529,221	Dec 09 04:15 PM
STEPHEN M FORTHUBER	Officer	Dec 05 '25	Proposed Sale	78.33	45,088	3,531,955		Dec 05 04:17 PM
Forthuber Stephen M	Pres & COO-Eastern Operations	Dec 03 '25	Option Exercise	6.07	39,127	237,501	574,309	Dec 03 08:00 AM
Berger Howard G	President, CEO	Nov 19 '25	Option Exercise	18.64	129,961	2,422,473	348,412	Nov 21 04:15 PM
Patel Mital	EVP of Fin Planning, CAO	Nov 17 '25	Sale	76.06	25,000	1,901,500	205,138	Nov 19 06:10 PM
Patel Mital	EVP of Fin Planning, CAO	Nov 19 '25	Sale	80.05	15,080	1,207,154	180,138	Nov 19 06:10 PM
Patel Mital	EVP of Fin Planning, CAO	Nov 18 '25	Sale	80.00	9,920	793,600	195,218	Nov 19 06:10 PM
Patel Mital	Officer	Nov 19 '25	Proposed Sale	107.81	25,000	2,695,142		Nov 19 04:41 PM
Patel Mital	Officer	Nov 18 '25	Proposed Sale	80.00	9,920	793,627		Nov 19 04:33 PM
Patel Mital	Officer	Nov 17 '25	Proposed Sale	76.06	25,000	1,901,486		Nov 19 04:26 PM
STOLPER MARK	EVP, Chief Financial Officer	Sep 16 '25	Sale	73.89	35,000	2,586,150	68,012	Sep 18 05:29 PM
Katz David Jeffrey	EVP and Chief Legal Officer	Sep 16 '25	Sale	74.44	14,000	1,042,160	68,181	Sep 17 04:15 PM
David Jeffrey Katz	Officer	Sep 16 '25	Proposed Sale	74.99	14,000	1,049,860		Sep 16 07:00 AM
STOLPER MARK	Officer	Sep 15 '25	Proposed Sale	74.01	35,000	2,590,350		Sep 15 04:40 PM
Wesdorp Cornelis	Pres & CEO, Digital Health	Sep 11 '25	Sale	72.13	500	36,065	53,495	Sep 15 07:00 AM
HAMES NORMAN R	Pres and COO-West Operations	Sep 10 '25	Sale	72.74	10,000	727,400	239,183	Sep 12 05:10 PM
Cornelis Wesdorp	Officer	Sep 11 '25	Proposed Sale	73.73	500	36,865		Sep 11 06:46 PM
HAMES NORMAN R	Officer	Sep 10 '25	Proposed Sale	72.69	10,000	726,892		Sep 10 06:29 PM
Wesdorp Cornelis	Pres & CEO, Digital Health	Sep 09 '25	Sale	71.99	500	35,995	53,995	Sep 10 04:27 PM
Cornelis Wesdorp	Officer	Aug 19 '25	Proposed Sale	72.73	2,000	145,460		Sep 09 05:28 PM
HAMES NORMAN R	Pres and COO-West Operations	Aug 27 '25	Sale	71.10	5,000	355,500	19,889	Aug 29 07:09 PM
Norman R. Hames	Member of Immed Family of Pres	Aug 27 '25	Proposed Sale	71.79	5,000	358,950		Aug 29 07:03 PM
Wesdorp Cornelis	Pres & CEO, Digital Health	Aug 19 '25	Sale	66.98	1,500	100,470	54,495	Aug 21 04:15 PM
Jayanathan Ranjan	Chief Information Officer	Aug 19 '25	Sale	67.50	65,598	4,427,865	138,198	Aug 21 04:15 PM
Jayanathan Ranjan	Officer	Aug 15 '25	Proposed Sale	63.60	70,000	4,452,000		Aug 15 11:22 AM
Katz David Jeffrey	EVP and Chief Legal Officer	Aug 13 '25	Sale	68.31	17,000	1,161,270	86,774	Aug 15 08:00 AM
Jayanathan Ranjan	Officer	Jun 12 '25	Proposed Sale	58.06	18,708	1,086,168		Jun 12 08:28 AM
Katz David Jeffrey	Officer	Jun 09 '25	Proposed Sale	58.65	17,000	997,050		Jun 09 10:54 AM
Murdock Michael N	EVP, Mergers and Acquisitions	Jun 05 '25	Sale	58.05	11,132	646,213	43,084	Jun 06 04:15 PM
Murdock Michael N	Officer	Jun 05 '25	Proposed Sale	58.49	11,132	651,110		Jun 05 10:50 AM
Sorensen Alma Gregory	EVP, Chief Science Officer	May 23 '25	Sale	56.48	55,000	3,106,400	1,160,509	May 27 04:15 PM
Sorensen Alma Gregory	EVP, Chief Science Officer	May 22 '25	Sale	57.06	45,000	2,567,700	1,215,509	May 27 04:15 PM
ALMA GREGORY SORENSEN & KRISTI	Director	May 23 '25	Proposed Sale	56.48	55,000	3,106,565		May 23 04:13 PM
ALMA GREGORY SORENSEN & KRISTI	Director	May 22 '25	Proposed Sale	57.06	45,000	2,567,830		May 22 04:12 PM
Forthuber Stephen M	Pres & COO-Eastern Operations	May 16 '25	Sale	60.34	18,820	1,135,599	535,182	May 20 04:15 PM
Levitt Lawrence L	Director	May 16 '25	Sale	61.09	5,000	305,450	164,957	May 20 04:15 PM
Lawrence L. Levitt	Director	May 16 '25	Proposed Sale	61.09	5,000	305,439		May 16 07:17 PM
STEPHEN M FORTHUBER	Officer	May 16 '25	Proposed Sale	60.48	18,820	1,138,299		May 16 04:10 PM
HAMES NORMAN R	Pres and COO-West Operations	May 15 '25	Sale	60.00	5,536	332,160	249,183	May 15 08:43 PM
HAMES NORMAN R	Pres and COO-West Operations	May 15 '25	Sale	60.00	2,911	174,660	24,889	May 15 08:43 PM
Norman R. Hames	Member of Immediate Family of	May 15 '25	Proposed Sale	60.00	2,911	174,661		May 15 08:43 PM
Norman R. Hames	President & COO-West Operation	May 15 '25	Proposed Sale	60.00	5,536	332,160		May 15 08:43 PM
Patel Mital	EVP of Fin Planning, CAO	Apr 04 '25	Option Exercise	8.61	50,340	433,315	230,138	Apr 08 08:00 AM

Open in Screener

FTRE

Fortrea Holdings Inc

Apr 02 • 04:00PM ET

9.45

-0.06 -0.63 %

Healthcare • Biotechnology • USA • NASD

FTRE Fortrea Holdings Inc daily Stock Chart

Peers: PFE JNJ MRK AMGN LLY BMY GILD REGN VRTX BIIB

| Held by: IJR VTI IWM FNDA VB VXF IJS SPSM IWN VBR

Index	RUT	P/E	-	EPS (ttm)	-10.91	Insider Own	0.54%	Shs Outstand	93.10M	Perf Week	-1.05%
Market Cap	883.57M	Forward P/E	10.34	EPS next Y	0.91	Insider Trans	-3.30%	Shs Float	93.00M	Perf Month	-8.96%
Enterprise Value	1.82B	PEG	0.24	EPS next Q	0.07	Inst Own	102.19%	Short Float	11.58%	Perf Quarter	-45.22%
Income	-986.20M	P/S	0.32	EPS this Y	58.98%	Inst Trans	-0.11%	Short Ratio	6.47	Perf Half Y	-0.74%
Sales	2.72B	P/B	1.56	EPS next Y	33.66%	ROA	-31.33%	Short Interest	10.77M	Perf YTD	-45.22%
Book/sh	6.05	P/C	5.06	EPS next 5Y	42.50%	ROE	-102.41%	52W High	18.67 -49.38%	Perf Year	25.83%
Cash/sh	1.87	P/FCF	10.01	EPS past 3/5Y	- -21.68%	ROIC	-59.21%	52W Low	3.97 138.04%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	36.07	Sales past 3/5Y	-4.19% 1.09%	Gross Margin	15.63%	Volatility	7.62% 7.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.67	EPS Y/Y TTM	-215.80%	Oper. Margin	-1.12%	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.98	Sales Y/Y TTM	1.00%	Profit Margin	-36.21%	RSI (14)	42.37	Recom	2.38
Dividend Gr. 3/5Y	- -	Current Ratio	0.98	EPS Q/Q	51.52%	SMA20	0.19%	Beta	1.77	Target Price	14.35
Payout	-	Debt/Eq	1.98	Sales Q/Q	-5.24%	SMA50	-18.80%	Rel Volume	0.51	Prev Close	9.51
Employees	14300	LT Debt/Eq	1.96	Earnings	Feb 26 BMO	SMA200	-11.29%	Avg Volume	1.66M	Price	9.45
IPO	Jun 16, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-46.81% -0.71%	Trades		Volume	845,544	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-09-26	Upgrade	TD Cowen	Hold → Buy	$15
Jan-08-26	Upgrade	Truist	Hold → Buy	$22
Jan-06-26	Upgrade	Evercore ISI	In-line → Outperform	$25
Dec-15-25	Upgrade	Barclays	Underweight → Equal Weight	$15
Dec-11-25	Upgrade	Citigroup	Neutral → Buy	$21
Aug-04-25	Upgrade	Robert W. Baird	Neutral → Outperform	$9
May-02-25	Initiated	Truist	Hold	$7
Apr-10-25	Downgrade	Barclays	Equal Weight → Underweight	$6
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$30 → $23
Dec-06-24	Downgrade	Robert W. Baird	Outperform → Neutral	$28 → $25
Sep-25-24	Downgrade	Jefferies	Buy → Hold	$25 → $21
Aug-08-24	Downgrade	Evercore ISI	Outperform → In-line	$31 → $27
Jul-24-24	Resumed	Barclays	Equal Weight	$30
Jun-06-24	Initiated	Goldman	Neutral	$28
May-29-24	Initiated	TD Cowen	Hold	$27
May-28-24	Initiated	Mizuho	Neutral	$27
Mar-22-24	Initiated	Robert W. Baird	Neutral	$43
Mar-06-24	Initiated	Deutsche Bank	Hold	$36
Jan-05-24	Initiated	William Blair	Mkt Perform
Jan-04-24	Initiated	Jefferies	Buy	$44

Show Previous Ratings

Mar-10-26 04:15PM	Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.95% +5.25%
Mar-03-26 10:35PM	Q4 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Mar-02-26 10:23AM	Fortrea Holdings Inc. (FTRE) 2026 Guidance Assumes Stable FX Rates from End-2025 (Insider Monkey)
Feb-27-26 12:44PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Feb-26-26 04:12PM	Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
03:48PM	Loading…
03:48PM	Fortrea Q4 Earnings Call Highlights (MarketBeat)
09:55AM	Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates (Zacks)
06:24AM	Fortrea (NASDAQ:FTRE) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings (StockStory)
06:00AM	Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance (GlobeNewswire)
Feb-25-26 09:49AM	Earnings To Watch: Fortrea (FTRE) Reports Q4 Results Tomorrow (StockStory)
Feb-18-26 11:03PM	3 Reasons to Sell FTRE and 1 Stock to Buy Instead (StockStory) +7.63% +5.46%
Feb-17-26 07:00AM	Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services (GlobeNewswire)
Feb-13-26 08:29PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
11:40AM	FTRE vs. PRTA: Which Stock Is the Better Value Option? (Zacks)
Feb-06-26 07:15AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates (Zacks) +6.16%
07:38PM	Loading…
Feb-05-26 07:38PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -14.07%
Feb-02-26 09:00AM	Curreen Capital: Fortrea (FTRE) is an Example of Our "Crazy Cheap" Strategy (Insider Monkey)
Jan-29-26 08:08AM	Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call (GlobeNewswire)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-16-26 04:11PM	Why Fortrea (FTRE) Stock Is Trading Up Today (StockStory)
12:13PM	Mizuho Increases Fortrea (FTRE) PT to $15 Despite Signs of Peaking Healthcare Trends (Insider Monkey)
Jan-14-26 08:55AM	Fortrea Holdings Inc. (FTRE) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Jan-12-26 11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks) +5.81%
Jan-09-26 11:24AM	Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 08:06AM	Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Jan-06-26 07:00AM	Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference (GlobeNewswire) +5.54%
Dec-19-25 03:16PM	Why Fortrea (FTRE) Stock Is Up Today (StockStory) +6.80%
Dec-18-25 11:50AM	Why Fortrea (FTRE) Stock Is Trading Up Today (StockStory)
Dec-11-25 07:17PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
02:16PM	Why Fortrea (FTRE) Stock Is Up Today (StockStory)
08:19PM	Loading…
Dec-10-25 08:19PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +5.21%
06:00PM	Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 07:00AM	SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery (GlobeNewswire)
Nov-25-25 01:01PM	Fortrea (FTRE) Stock Trades Up, Here Is Why (StockStory) +6.95%
07:00AM	Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences (GlobeNewswire)
Nov-24-25 06:46PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +9.63%
07:00AM	Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand (GlobeNewswire)
Nov-17-25 07:00AM	Fortrea Appoints Agnieszka Gallagher as General Counsel (GlobeNewswire) -5.96%
Nov-13-25 10:56PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -9.88%
Nov-12-25 12:36AM	5 Insightful Analyst Questions From Fortrea's Q3 Earnings Call (StockStory)
Nov-11-25 10:35PM	Q3 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory) +5.46%
10:56AM	Stock Market Today: U.S. Stocks Fall As SoftBank Disposes of Nvidia Stake, ADP Reports Job Losses (TheStreet)
Nov-06-25 05:50PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -7.78%
12:32AM	FTRE Q3 Deep Dive: Revenue Outpaces Estimates, Margin Expansion Remains a Focus (StockStory)
Nov-05-25 07:32PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +23.20%
02:55PM	Why Fortrea (FTRE) Stock Is Trading Up Today (StockStory)
02:02PM	Fortrea Holdings Inc (FTRE) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic ... (GuruFocus.com)
07:40AM	Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates (Zacks)
07:02AM	Fortrea (NASDAQ:FTRE) Beats Q3 Sales Expectations (StockStory)
06:30AM	Fortrea Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-03-25 10:08PM	Fortrea (FTRE) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-27-25 06:57PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -8.05%
Oct-24-25 06:43PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Oct-20-25 01:35PM	Why Fortrea (FTRE) Stock Is Trading Up Today (StockStory) +10.26%
07:00AM	Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt (GlobeNewswire)
Oct-15-25 07:00AM	Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call (GlobeNewswire)
Oct-13-25 07:31AM	5 Value Picks to Ride Out US-China Trade Rift & Government Shutdown (Zacks)
Oct-11-25 09:48AM	Barclays Lifts Fortrea (FTRE) PT to $8 Amid Q3 2025 Life Sciences Preview (Insider Monkey)
Oct-08-25 01:45PM	Why Fortrea (FTRE) Stock Is Up Today (StockStory) +8.81%
Oct-06-25 09:41AM	Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
Sep-25-25 05:10PM	Why Fortrea (FTRE) Shares Are Sliding Today (StockStory) -5.81%
Sep-22-25 04:30PM	Fortrea Appoints William Sharbaugh to Board of Directors (GlobeNewswire)
Sep-12-25 04:15PM	Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-11-25 02:15PM	Jefferies Raises Fortrea (FTRE) PT to $9.50 Amid Improved Biotech Funding (Insider Monkey)
Sep-08-25 06:57PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -11.26%
Sep-05-25 07:03PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +10.66%
Sep-03-25 12:36PM	Why Fortrea (FTRE) Stock Is Trading Up Today (StockStory) +6.79%
Aug-27-25 12:02AM	3 Reasons FTRE is Risky and 1 Stock to Buy Instead (StockStory)
Aug-25-25 09:55AM	Investors who lost money with Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire) +6.30%
Aug-22-25 07:02PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +7.62%
Aug-21-25 11:37PM	Reflecting On Drug Development Inputs & Services Stocks' Q2 Earnings: Fortrea (NASDAQ:FTRE) (StockStory)
Aug-19-25 12:09AM	Jefferies Raises PT on Fortrea Holdings Inc. (FTRE); Truist Financial Maintains 'Hold' Rating (Insider Monkey)
Aug-13-25 01:37AM	5 Insightful Analyst Questions From Fortrea's Q2 Earnings Call (StockStory) +7.25%
Aug-12-25 08:00AM	Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial (PR Newswire) +14.40%
03:18AM	FTRE Q2 Deep Dive: Revenue Growth Driven by Clinical Pharmacology and Operational Restructuring (StockStory)
Aug-07-25 08:48PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +10.03% -9.12%
Aug-06-25 01:20PM	Why Fortrea (FTRE) Shares Are Sliding Today (StockStory)
07:45AM	Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:36AM	Fortrea (NASDAQ:FTRE) Reports Bullish Q2, Stock Soars (StockStory)
06:30AM	Fortrea Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 06:00PM	Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations (GlobeNewswire)
08:15AM	AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-04-25 11:06PM	Fortrea (FTRE) Reports Earnings Tomorrow: What To Expect (StockStory) +17.58%
04:30PM	Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 08:00AM	Avant Technologies and Ainnova Tech Advance Clinical Trial Protocol Following FDA Feedback (PR Newswire) -7.42%
07:20AM	Curreen Capital's Investment Thesis for Fortrea Holdings Inc (FTRE) (Insider Monkey)
Jul-23-25 03:36PM	Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know (StockStory) +8.79%
Jul-22-25 02:05PM	Why Are Fortrea (FTRE) Shares Soaring Today (StockStory) +24.46%
08:45AM	Investors in Fortrea Holdings Inc. Should Contact Levi & Korsinsky Before August 1, 2025 to Discuss Your Rights - FTRE (PR Newswire)
Jul-18-25 08:45AM	Fortrea Holdings Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - FTRE (PR Newswire) -5.25%
Jul-16-25 07:00AM	Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call (GlobeNewswire)
Jul-15-25 08:58AM	Fortrea, Emery Pharma Partner for Rapid MNP Testing in Rifampin, Enables FDA-Compliant DDI Studies (Insider Monkey) -5.79%
08:00AM	Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA (PR Newswire)
Jul-11-25 12:51PM	Why Fortrea (FTRE) Shares Are Falling Today (StockStory)
10:46AM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
09:00AM	Investors in Fortrea Holdings Inc. Should Contact Levi & Korsinsky Before August 1, 2025 to Discuss Your Rights - FTRE (PR Newswire)
Jul-07-25 08:06AM	Here's Why Penn Davis McFarland Sold Fortrea Holdings (FTRE) in Q1 (Insider Monkey) -14.75%
Jun-30-25 08:55AM	5 Must-Read Analyst Questions From Fortrea's Q1 Earnings Call (StockStory)
08:00AM	Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting (PR Newswire)

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Russell Erin L	Director	Mar 20 '26	Option Exercise	0.00	23,946	0	33,800	Mar 24 04:05 PM
Morais Mark A.	Chief Operating Officer	Mar 13 '26	Option Exercise	0.00	4,284	0	71,703	Mar 17 04:08 PM
Morais Mark A.	Chief Operating Officer	Mar 16 '26	Sale	9.22	1,804	16,633	69,899	Mar 17 04:08 PM
Mcconnell Jill G.	Chief Financial Officer	Mar 13 '26	Option Exercise	0.00	4,284	0	74,080	Mar 17 04:06 PM
Mcconnell Jill G.	Chief Financial Officer	Mar 16 '26	Sale	9.22	1,804	16,633	72,276	Mar 17 04:06 PM
Mcconnell Jill G.	Officer	Mar 16 '26	Proposed Sale	9.22	1,804	16,627		Mar 16 04:13 PM
Morais Mark A.	Officer	Mar 16 '26	Proposed Sale	9.22	1,804	16,627		Mar 16 04:08 PM
Parks Robert	Chief Accounting Officer	Mar 09 '26	Option Exercise	0.00	5,270	0	24,316	Mar 11 05:16 PM
Parks Robert	Chief Accounting Officer	Mar 10 '26	Sale	9.07	1,927	17,478	22,389	Mar 11 05:16 PM
Morais Mark A.	Chief Operating Officer	Mar 09 '26	Option Exercise	0.00	13,966	0	72,018	Mar 11 05:14 PM
Morais Mark A.	Chief Operating Officer	Mar 10 '26	Sale	9.07	4,599	41,713	67,419	Mar 11 05:14 PM
Mcconnell Jill G.	Chief Financial Officer	Mar 09 '26	Option Exercise	0.00	15,283	0	74,857	Mar 11 05:10 PM
Mcconnell Jill G.	Chief Financial Officer	Mar 10 '26	Sale	9.07	5,061	45,903	69,796	Mar 11 05:10 PM
Morais Mark A.	Officer	Mar 10 '26	Proposed Sale	9.07	4,599	41,717		Mar 10 03:31 PM
Parks Robert	Officer	Mar 10 '26	Proposed Sale	9.07	1,927	17,480		Mar 10 03:27 PM
Mcconnell Jill G.	Officer	Mar 10 '26	Proposed Sale	9.07	5,061	45,908		Mar 10 03:13 PM
Morais Mark A.	Chief Operating Officer	Feb 09 '26	Option Exercise	0.00	2,255	0	59,231	Feb 11 07:04 PM
Morais Mark A.	Chief Operating Officer	Feb 10 '26	Sale	13.88	1,179	16,365	58,052	Feb 11 07:04 PM
Mcconnell Jill G.	Chief Financial Officer	Feb 09 '26	Option Exercise	0.00	1,685	0	60,455	Feb 11 07:02 PM
Mcconnell Jill G.	Chief Financial Officer	Feb 10 '26	Sale	13.88	881	12,229	59,574	Feb 11 07:02 PM
Mcconnell Jill G.	Officer	Feb 10 '26	Proposed Sale	13.88	881	12,230		Feb 10 04:21 PM
Morais Mark A.	Officer	Feb 10 '26	Proposed Sale	13.88	1,179	16,367		Feb 10 04:19 PM
Hanson James S.	Former Officer	Jan 20 '26	Proposed Sale	15.57	27,736	431,935		Jan 20 03:30 PM
Parks Robert	Chief Accounting Officer	Sep 15 '25	Option Exercise	0.00	24,934	0	26,384	Sep 17 04:16 PM
Parks Robert	Chief Accounting Officer	Sep 16 '25	Sale	9.95	7,338	73,013	19,046	Sep 17 04:16 PM
Parks Robert	Officer	Sep 16 '25	Proposed Sale	9.95	7,338	73,008		Sep 16 03:24 PM
Parks Robert	Chief Accounting Officer	Sep 08 '25	Option Exercise	0.00	2,042	0	2,042	Sep 10 04:36 PM
Parks Robert	Chief Accounting Officer	Sep 09 '25	Sale	10.23	592	6,056	1,450	Sep 10 04:36 PM
Hanson James S.	General Counsel	Sep 08 '25	Option Exercise	0.00	5,788	0	20,769	Sep 10 04:34 PM
Hanson James S.	General Counsel	Sep 09 '25	Sale	10.23	1,677	17,156	19,092	Sep 10 04:34 PM
Morais Mark A.	Chief Operating Officer	Sep 08 '25	Option Exercise	0.00	7,156	0	60,131	Sep 10 04:32 PM
Morais Mark A.	Chief Operating Officer	Sep 09 '25	Sale	10.23	3,155	32,276	56,976	Sep 10 04:32 PM
Mcconnell Jill G.	Chief Financial Officer	Sep 08 '25	Option Exercise	0.00	7,156	0	61,926	Sep 10 04:30 PM
Mcconnell Jill G.	Chief Financial Officer	Sep 09 '25	Sale	10.23	3,156	32,286	58,770	Sep 10 04:30 PM
Morais Mark A.	Officer	Sep 09 '25	Proposed Sale	10.23	3,155	32,273		Sep 09 04:48 PM
Parks Robert	Officer	Sep 09 '25	Proposed Sale	10.23	592	6,056		Sep 09 04:44 PM
Hanson James S.	Officer	Sep 09 '25	Proposed Sale	10.23	1,677	17,154		Sep 09 04:44 PM
Mcconnell Jill G.	Officer	Sep 09 '25	Proposed Sale	10.23	3,156	32,283		Sep 09 04:40 PM
Russell Erin L	Director	Sep 02 '25	Buy	10.15	9,854	100,018	9,854	Sep 04 04:39 PM
Morais Mark A.	Chief Operating Officer	Aug 18 '25	Option Exercise	0.00	11,312	0	57,861	Aug 20 05:25 PM
Morais Mark A.	Chief Operating Officer	Aug 19 '25	Sale	8.01	4,886	39,137	52,975	Aug 20 05:25 PM
Mcconnell Jill G.	Chief Financial Officer	Aug 18 '25	Option Exercise	0.00	11,312	0	59,656	Aug 20 05:23 PM
Mcconnell Jill G.	Chief Financial Officer	Aug 19 '25	Sale	8.01	4,886	39,137	54,770	Aug 20 05:23 PM
Morais Mark A.	Officer	Aug 19 '25	Proposed Sale	8.01	4,886	39,160		Aug 19 03:22 PM
Mcconnell Jill G.	Officer	Aug 19 '25	Proposed Sale	8.01	4,886	39,160		Aug 19 03:14 PM
NEUPERT PETER M	Director	Aug 08 '25	Buy	6.79	30,000	203,700	65,632	Aug 11 08:21 PM
NEUPERT PETER M	Director	Aug 11 '25	Buy	6.26	32,500	203,450	98,132	Aug 11 08:21 PM
Morais Mark A.	Chief Operating Officer	Jun 02 '25	Option Exercise	0.00	11,007	0	49,679	Jun 04 05:44 PM
Morais Mark A.	Chief Operating Officer	Jun 03 '25	Sale	4.17	3,130	13,052	46,549	Jun 04 05:44 PM
Mcconnell Jill G.	Chief Financial Officer	Jun 02 '25	Option Exercise	0.00	11,007	0	51,474	Jun 04 05:43 PM
Mcconnell Jill G.	Chief Financial Officer	Jun 03 '25	Sale	4.17	3,130	13,052	48,344	Jun 04 05:43 PM
Hanson James S.	General Counsel	Jun 02 '25	Option Exercise	0.00	7,706	0	17,172	Jun 04 05:42 PM
Hanson James S.	General Counsel	Jun 03 '25	Sale	4.17	2,191	9,136	14,981	Jun 04 05:42 PM
Mcconnell Jill G.	Officer	Jun 03 '25	Proposed Sale	4.17	3,130	13,050		Jun 03 03:25 PM
Morais Mark A.	Officer	Jun 03 '25	Proposed Sale	4.17	3,130	13,050		Jun 03 03:23 PM
Hanson James S.	Officer	Jun 03 '25	Proposed Sale	4.17	2,191	9,135		Jun 03 03:15 PM
Smith David Ross	Director	May 14 '25	Option Exercise	0.00	7,282	0	11,729	May 16 04:51 PM
Pesicka Edward A	Director	May 14 '25	Option Exercise	0.00	7,282	0	13,636	May 16 04:49 PM
Ray Amrit	Director	May 14 '25	Option Exercise	0.00	7,282	0	13,636	May 16 04:47 PM
SANDERS MACHELLE	Director	May 14 '25	Option Exercise	0.00	7,282	0	7,282	May 16 04:45 PM
NEUPERT PETER M	Chief Executive Officer	May 14 '25	Option Exercise	0.00	7,282	0	35,632	May 16 04:42 PM

Open in Screener

GH

Guardant Health Inc

Apr 02 • 04:00PM ET

93.83

+2.68 2.94 %

Healthcare • Diagnostics & Research • USA • NASD

GH Guardant Health Inc daily Stock Chart

Peers: ILMN QGEN EXAS FLGT BIO SRPT MYGN NTRA CDNA TXG

| Held by: VTI IWM VB VBK VXF IWO SCHA VTWO ARKG CGGR

Index	RUT	P/E	-	EPS (ttm)	-3.31	Insider Own	3.80%	Shs Outstand	130.64M	Perf Week	6.50%
Market Cap	12.31B	Forward P/E	-	EPS next Y	-1.93	Insider Trans	-8.98%	Shs Float	126.19M	Perf Month	0.87%
Enterprise Value	12.82B	PEG	-	EPS next Q	-0.81	Inst Own	100.79%	Short Float	9.08%	Perf Quarter	-8.14%
Income	-416.28M	P/S	12.53	EPS this Y	11.04%	Inst Trans	6.02%	Short Ratio	5.68	Perf Half Y	49.77%
Sales	982.02M	P/B	-	EPS next Y	34.53%	ROA	-23.79%	Short Interest	11.45M	Perf YTD	-8.14%
Book/sh	-0.76	P/C	10.24	EPS next 5Y	65.70%	ROE	-	52W High	120.74 -22.29%	Perf Year	115.75%
Cash/sh	9.16	P/FCF	-	EPS past 3/5Y	19.67% -4.99%	ROIC	-26.29%	52W Low	36.36 158.06%	Perf 3Y	300.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	29.75% 27.92%	Gross Margin	64.46%	Volatility	5.97% 4.83%	Perf 5Y	-40.23%
Dividend TTM	-	EV/Sales	13.05	EPS Y/Y TTM	6.77%	Oper. Margin	-44.47%	ATR (14)	4.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.56	Sales Y/Y TTM	32.88%	Profit Margin	-42.39%	RSI (14)	54.72	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	4.84	EPS Q/Q	-11.34%	SMA20	6.67%	Beta	1.67	Target Price	130.64
Payout	-	Debt/Eq	-	Sales Q/Q	39.37%	SMA50	-4.00%	Rel Volume	0.87	Prev Close	91.15
Employees	2506	LT Debt/Eq	-	Earnings	Feb 19 AMC	SMA200	17.53%	Avg Volume	2.02M	Price	93.83
IPO	Oct 04, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-30.41% 3.25%	Trades		Volume	1,743,890	Change	2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-26	Reiterated	Canaccord Genuity	Buy	$125 → $135
Feb-17-26	Initiated	Robert W. Baird	Outperform	$120
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Dec-02-25	Resumed	Morgan Stanley	Overweight	$130
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$75
Sep-22-25	Resumed	Wells Fargo	Overweight	$72
Apr-10-25	Initiated	Mizuho	Outperform	$55
Jan-23-25	Initiated	Barclays	Overweight	$60
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy	$36
Jun-03-24	Resumed	Jefferies	Buy	$32
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33

Show Previous Ratings

Mar-30-26 08:05AM	Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan (Business Wire)
08:00AM	Gamehost Enters into Definitive Agreement to Be Acquired by Pure Casino Entertainment for $13.65 per Share (TMX Newsfile)
Mar-24-26 09:15AM	Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data (PR Newswire)
Mar-18-26 08:53PM	Gamehost to Correct Administrative Expense Allocation in Financial Statements; No Impact on Operations or Cash Flow (TMX Newsfile)
08:05AM	Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 (Business Wire)
08:05AM	Loading…
Mar-16-26 08:05AM	Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership (Business Wire)
Mar-13-26 08:05AM	New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare (Business Wire)
Mar-10-26 08:05AM	Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics (Business Wire)
Mar-05-26 11:51AM	BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? (Zacks)
08:44AM	TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? (Zacks)
Mar-04-26 07:00AM	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America (Business Wire)
Mar-03-26 07:00AM	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened (Business Wire)
Mar-02-26 02:57AM	Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition (Insider Monkey)
Feb-27-26 04:05PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-26-26 05:00PM	Grail's Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech. (Barrons.com)
07:48AM	Loading…
07:48AM	Guardant Health (GH) Gained from Better-Than-Expected Results (Insider Monkey)
Feb-23-26 06:50PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -8.42%
01:20PM	Guardant Health acquires MetaSight amid positive 2026 financial outlook (Medical Device Network)
12:00PM	Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know (StockStory)
12:52AM	Guardant buys MetaSight for $59M upfront to acquire blood test tech (MedTech Dive)
Feb-20-26 08:30AM	Guardant Health, Inc. Q4 2025 Earnings Call Summary (Moby)
12:02AM	Guardant Health Inc (GH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-19-26 09:10PM	Guardant Health Q4 Earnings Call Highlights (MarketBeat)
07:00PM	Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics (Zacks)
06:00PM	Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:02PM	Guardant Health: Q4 Earnings Snapshot (Associated Press Finance)
04:42PM	Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales (StockStory)
04:05PM	Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (Business Wire)
Feb-18-26 05:04PM	Walmart To Report Results, Fresh Off New Highs, A New CEO And $1 Trillion Market Cap (Investor's Business Daily)
Feb-17-26 10:08PM	Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow (StockStory)
06:48PM	Loading…
06:48PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
10:09AM	What Makes Guardant Health (GH) a Good Healthcare Holding (Insider Monkey)
08:04AM	Palo Alto Earnings Due. How Will Deal Blitz Impact Guidance? (Investor's Business Daily)
Feb-14-26 09:37AM	Boeing Holds In Buy Zone, Leads 5 Stocks To Watch In Short Trading Week (Investor's Business Daily)
Feb-13-26 08:22PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
03:38PM	IPO Stock Of The Week: Health Care Leader BrightSpring Eyes New Buy Point (Investor's Business Daily)
10:20AM	Walmart Stock, Parade Of Gold Leaders Headline Another Busy Earnings Calendar (Investor's Business Daily)
Feb-12-26 02:35PM	Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open (PR Newswire)
10:00AM	Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
Feb-11-26 07:28PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Feb-06-26 07:15AM	Long-Time Bear On Palantir Stock Says More Selling Still To Come (Investor's Business Daily)
Feb-05-26 07:32PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -7.34%
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 05:45PM	Palantir Retreats After Q4 Earnings Pop. Will 'N of 1' Story Work? (Investor's Business Daily) -6.10%
Feb-03-26 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
08:03AM	Stock Market Week: Dow Rally Aces Ninth Month (Investor's Business Daily)
Feb-02-26 04:27PM	Palantir Rebuts Bears With Earnings Beat, Guidance Above Views (Investor's Business Daily)
08:05AM	Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions (Business Wire)
Jan-30-26 05:04AM	Should You Buy Guardant Health Before Feb. 19? (Motley Fool)
Jan-29-26 04:05PM	Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
Jan-23-26 07:40AM	Wall Street Has a Positive Opinion on Guardant Health (GH) (Insider Monkey)
Jan-22-26 12:51PM	FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer (Benzinga)
08:05AM	Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for BRAFTOVI (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer (Business Wire)
Jan-20-26 08:54AM	Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 (Insider Monkey)
04:58AM	Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build (Insider Monkey)
Jan-19-26 08:05AM	Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform (Business Wire)
Jan-17-26 05:30AM	Supersize CEO Pay Packages Aren't Paying Off for Shareholders (The Wall Street Journal)
Jan-14-26 10:35PM	Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group (StockStory)
Jan-11-26 05:00PM	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
01:10AM	Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH) (Insider Monkey)
Jan-10-26 08:00AM	Google, Shopify Lead Big 2025 Winners Near New Buy Points (Investor's Business Daily)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 01:30PM	Guardant Health Catapults 234%; Sets Up With Strong Sales Outlook (Investor's Business Daily)
10:31AM	Cathie Wood Dumps $12.7 Million Worth of Meta Stock Amid Ray-Ban Smart Glasses Delay, Ark Loads Up On This Gaming Platform (Benzinga)
08:05AM	Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families (Business Wire)
Jan-06-26 06:54PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +10.27%
Dec-31-25 11:33AM	Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside (Insider Monkey)
Dec-29-25 04:05PM	Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:59AM	Stock Market Today: Dow Down From Record Highs; Nvidia, Tesla Slide (Live Coverage) (Investor's Business Daily)
Dec-27-25 08:05AM	Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 (Investor's Business Daily)
Dec-26-25 05:23PM	Dow Jones Futures: Tesla, Nvidia Lead 5 Giants In Buy Areas; Market Strong As 2025 Nears End (Investor's Business Daily)
03:41PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-22-25 10:19PM	Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth (Insider Monkey)
Dec-16-25 10:41AM	Guardant Health price target raised to $120 from $100 at BofA (TipRanks)
Dec-11-25 08:05AM	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. (Business Wire)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
08:05AM	Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy (Business Wire)
Dec-08-25 10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
Dec-05-25 06:42PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -5.99%
09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
08:05AM	Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium (Business Wire)
Dec-04-25 09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-03-25 03:27PM	Why Guardant Health (GH) Stock Is Up Today (StockStory)
Nov-24-25 06:40PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +5.53%
Nov-23-25 11:03PM	Guardant Health (GH): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
01:00PM	The marketing guru who helped turn Khosla Ventures into an AI powerhouse is moving on (TechCrunch)
10:34AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron (The Wall Street Journal)
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-12-25 08:05AM	Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access (Business Wire)
Nov-10-25 08:05AM	Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring (Business Wire)
Nov-07-25 08:00AM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-25 06:35PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:05AM	New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response (Business Wire)
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
Nov-05-25 04:05PM	Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients (Business Wire)
12:26PM	Why Guardant Health (GH) Shares Are Sliding Today (StockStory)
02:15AM	Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering (Business Wire)

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saia John G.	Chief Legal Officer	Apr 01 '26	Option Exercise	0.00	11,461	0	68,364	Apr 02 05:24 PM
Monroe Terilyn J.	Chief People Officer	Apr 01 '26	Option Exercise	0.00	8,019	0	29,009	Apr 02 05:23 PM
Kalia Kumud	Chief Information Officer	Apr 01 '26	Option Exercise	0.00	10,044	0	54,341	Apr 02 05:22 PM
Freeman Chris	Chief Commercial Officer	Apr 01 '26	Option Exercise	0.00	11,213	0	64,784	Apr 02 05:22 PM
EAGLE CRAIG	Chief Medical Officer	Apr 01 '26	Option Exercise	0.00	11,400	0	77,780	Apr 02 05:21 PM
Chudova Darya	Chief Technology Officer	Apr 01 '26	Option Exercise	0.00	13,029	0	77,381	Apr 02 05:21 PM
Bell Michael Brian	Chief Financial Officer	Apr 01 '26	Option Exercise	0.00	12,777	0	56,378	Apr 02 05:20 PM
Talasaz AmirAli	Co-Chief Executive Officer	Mar 31 '26	Option Exercise	0.00	2,817	0	2,131,306	Apr 02 05:19 PM
Talasaz AmirAli	Co-Chief Executive Officer	Apr 01 '26	Option Exercise	0.00	33,713	0	2,163,591	Apr 02 05:19 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Mar 31 '26	Option Exercise	0.00	2,817	0	2,097,721	Apr 02 05:19 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Apr 01 '26	Option Exercise	0.00	33,713	0	2,130,006	Apr 02 05:19 PM
Krognes Steve E.	Director	Mar 31 '26	Option Exercise	0.00	155	0	19,208	Apr 01 05:31 PM
MIGNONE ROBERTO	Director	Mar 21 '26	Option Exercise	0.00	264	0	4,487	Mar 23 04:19 PM
Tariq Musa	Director	Mar 18 '26	Sale	88.09	348	30,655	8,394	Mar 19 05:16 PM
Hidalgo Medina Manuel	Director	Mar 17 '26	Option Exercise	0.00	232	0	1,425	Mar 18 05:40 PM
Tariq Musa	Director	Mar 18 '26	Proposed Sale	88.09	348	30,655		Mar 18 04:05 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	38,283	0	2,134,594	Mar 17 09:57 PM
Talasaz AmirAli	Co-Chief Executive Officer	Mar 13 '26	Option Exercise	0.00	26,961	0	2,142,153	Mar 17 09:57 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	38,283	0	2,101,009	Mar 17 09:57 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Mar 13 '26	Option Exercise	0.00	26,961	0	2,108,568	Mar 17 09:57 PM
Tariq Musa	Director	Mar 15 '26	Option Exercise	0.00	249	0	8,742	Mar 17 06:49 PM
Saia John G.	Chief Legal Officer	Mar 15 '26	Option Exercise	0.00	8,811	0	61,525	Mar 17 06:49 PM
Kalia Kumud	Chief Information Officer	Mar 15 '26	Option Exercise	0.00	13,493	0	51,136	Mar 17 06:48 PM
Freeman Chris	Chief Commercial Officer	Mar 15 '26	Option Exercise	0.00	16,828	0	60,698	Mar 17 06:48 PM
EAGLE CRAIG	Chief Medical Officer	Mar 15 '26	Option Exercise	0.00	15,114	0	74,041	Mar 17 06:46 PM
Chudova Darya	Chief Technology Officer	Mar 15 '26	Option Exercise	0.00	10,714	0	70,111	Mar 17 06:46 PM
Bell Michael Brian	Chief Financial Officer	Mar 15 '26	Option Exercise	0.00	13,790	0	54,014	Mar 17 06:46 PM
Bell Michael Brian	Chief Financial Officer	Mar 16 '26	Sale	87.04	3,000	261,111	43,601	Mar 17 06:46 PM
Bell Michael Brian	Officer	Mar 16 '26	Proposed Sale	87.04	3,000	261,111		Mar 16 04:07 PM
Hidalgo Medina Manuel	Director	Mar 06 '26	Option Exercise	32.55	1,000	32,550	2,493	Mar 09 06:38 PM
Hidalgo Medina Manuel	Director	Mar 06 '26	Sale	91.54	1,300	118,997	1,193	Mar 09 06:38 PM
Hidalgo Medina Manuel	Director	Mar 06 '26	Proposed Sale	91.54	1,300	118,997		Mar 06 04:19 PM
Kalia Kumud	Chief Information Officer	Mar 04 '26	Option Exercise	37.48	43,119	1,616,117	77,643	Mar 05 05:44 PM
Kalia Kumud	Chief Information Officer	Mar 04 '26	Sale	95.32	40,000	3,812,661	37,643	Mar 05 05:44 PM
Kalia Kumud	Officer	Mar 04 '26	Proposed Sale	95.32	40,000	3,812,660		Mar 04 04:06 PM
Krognes Steve E.	Director	Feb 28 '26	Option Exercise	0.00	154	0	19,053	Mar 02 04:24 PM
MIGNONE ROBERTO	Director	Feb 21 '26	Option Exercise	0.00	264	0	4,223	Feb 23 05:47 PM
Hidalgo Medina Manuel	Director	Feb 17 '26	Option Exercise	0.00	232	0	1,493	Feb 18 04:27 PM
Tariq Musa	Director	Feb 15 '26	Option Exercise	0.00	250	0	8,493	Feb 17 06:31 PM
Krognes Steve E.	Director	Jan 31 '26	Option Exercise	0.00	154	0	18,899	Feb 02 04:30 PM
Monroe Terilyn J.	Chief People Officer	Jan 21 '26	Sale	114.09	8,571	977,902	20,990	Jan 22 05:45 PM
MIGNONE ROBERTO	Director	Jan 21 '26	Option Exercise	0.00	264	0	3,959	Jan 22 05:44 PM
Monroe Terilyn J.	Officer	Jan 21 '26	Proposed Sale	114.09	8,571	977,902		Jan 21 04:10 PM
Hidalgo Medina Manuel	Director	Jan 17 '26	Option Exercise	0.00	232	0	1,261	Jan 20 04:47 PM
Tariq Musa	Director	Jan 15 '26	Option Exercise	0.00	250	0	8,243	Jan 16 04:39 PM
Monroe Terilyn J.	Chief People Officer	Jan 15 '26	Option Exercise	0.00	17,379	0	38,369	Jan 16 04:39 PM
Monroe Terilyn J.	Chief People Officer	Jan 07 '26	Sale	112.08	10,031	1,124,279	20,990	Jan 09 04:09 PM
Monroe Terilyn J.	Officer	Jan 07 '26	Proposed Sale	112.07	10,031	1,124,200		Jan 07 04:03 PM
Saia John G.	Chief Legal Officer	Jan 01 '26	Option Exercise	0.00	19,046	0	62,703	Jan 05 06:01 PM
Monroe Terilyn J.	Chief People Officer	Jan 01 '26	Option Exercise	0.00	17,555	0	38,545	Jan 05 06:01 PM
Kalia Kumud	Chief Information Officer	Jan 01 '26	Option Exercise	0.00	21,237	0	43,916	Jan 05 06:00 PM
Freeman Chris	Chief Commercial Officer	Jan 01 '26	Option Exercise	0.00	27,237	0	54,032	Jan 05 05:59 PM
EAGLE CRAIG	Chief Medical Officer	Jan 01 '26	Option Exercise	0.00	25,442	0	70,449	Jan 05 05:58 PM
Chudova Darya	Chief Technology Officer	Jan 01 '26	Option Exercise	0.00	22,732	0	29,744	Jan 05 05:57 PM
Bell Michael Brian	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	23,038	0	52,703	Jan 05 05:57 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,002,689	Jan 05 05:56 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,024,245	Jan 05 05:56 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,051,958	Jan 05 05:55 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,073,514	Jan 05 05:55 PM
Krognes Steve E.	Director	Dec 31 '25	Option Exercise	0.00	154	0	18,745	Jan 05 05:54 PM
MIGNONE ROBERTO	Director	Dec 21 '25	Option Exercise	0.00	264	0	3,695	Dec 23 07:25 PM
Hidalgo Medina Manuel	Director	Dec 17 '25	Option Exercise	0.00	232	0	1,029	Dec 18 06:34 PM
Tariq Musa	Director	Dec 17 '25	Sale	101.46	116	11,769	7,993	Dec 18 06:33 PM
Tariq Musa	Director	Dec 15 '25	Option Exercise	0.00	250	0	8,109	Dec 17 07:21 PM
Saia John G.	Chief Legal Officer	Dec 15 '25	Option Exercise	0.00	1,020	0	44,192	Dec 17 07:20 PM
Kalia Kumud	Chief Information Officer	Dec 15 '25	Option Exercise	0.00	637	0	23,002	Dec 17 07:20 PM
Freeman Chris	Chief Commercial Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	27,389	Dec 17 07:19 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 15 '25	Sale	103.82	90,565	9,402,220	2,047,143	Dec 17 07:18 PM
EAGLE CRAIG	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	45,718	Dec 17 07:18 PM
Chudova Darya	Chief Technology Officer	Dec 15 '25	Sale	104.04	5,451	567,132	7,012	Dec 17 07:17 PM
Bell Michael Brian	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	3,272	0	31,324	Dec 17 07:17 PM
Tariq Musa	Director	Dec 17 '25	Proposed Sale	101.46	116	11,769		Dec 17 04:58 PM
Eltoukhy Helmy	Officer	Dec 15 '25	Proposed Sale	103.82	90,565	9,402,223		Dec 15 05:08 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 08 '25	Sale	105.05	100,000	10,505,474	168,223	Dec 10 09:33 PM
Kalia Kumud	Chief Information Officer	Dec 08 '25	Sale	104.60	2,000	209,204	22,365	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Option Exercise	32.55	1,000	32,550	2,047	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Sale	105.00	1,250	131,250	797	Dec 10 09:32 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	105.04	13,664	1,435,227	54,480	Dec 10 09:31 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	106.00	9,271	982,753	12,463	Dec 10 09:31 PM
Freeman Chris	Chief Commercial Officer	Dec 05 '25	Sale	103.07	31,452	3,241,621	25,987	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Option Exercise	30.71	56,287	1,728,787	108,414	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Sale	103.14	80,362	8,288,742	28,052	Dec 08 09:37 PM
CLARK IAN T	Director	Dec 05 '25	Option Exercise	35.83	28,611	1,025,156	38,462	Dec 08 09:36 PM
CLARK IAN T	Director	Dec 05 '25	Sale	107.19	28,611	3,066,817	9,851	Dec 08 09:36 PM
Talasaz AmirAli	Officer	Dec 08 '25	Proposed Sale	105.05	100,000	10,505,470		Dec 08 05:50 PM
Chudova Darya	Officer	Dec 08 '25	Proposed Sale	105.43	28,780	3,034,203		Dec 08 04:47 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Proposed Sale	105.00	1,250	131,250		Dec 08 04:46 PM
Kalia Kumud	Officer	Dec 08 '25	Proposed Sale	104.60	2,000	209,204		Dec 08 04:44 PM
Freeman Chris	Officer	Dec 05 '25	Proposed Sale	103.07	31,452	3,241,621		Dec 05 05:22 PM
CLARK IAN T	Director	Dec 05 '25	Proposed Sale	107.19	28,611	3,066,818		Dec 05 05:21 PM
Bell Michael Brian	Officer	Dec 05 '25	Proposed Sale	103.14	80,362	8,288,741		Dec 05 05:20 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Option Exercise	22.68	50,000	1,134,050	76,087	Dec 03 09:30 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Sale	105.97	55,167	5,846,163	20,920	Dec 03 09:30 PM
Krognes Steve E.	Director	Nov 30 '25	Option Exercise	0.00	155	0	18,591	Dec 01 09:41 PM
Monroe Terilyn J.	Officer	Dec 01 '25	Proposed Sale	105.97	55,167	5,846,164		Dec 01 04:56 PM
MIGNONE ROBERTO	Director	Nov 21 '25	Option Exercise	0.00	264	0	3,431	Nov 24 06:21 PM
Tariq Musa	Director	Nov 19 '25	Sale	96.25	116	11,165	7,859	Nov 20 09:27 PM
Tariq Musa	Director	Nov 19 '25	Proposed Sale	96.25	116	11,165		Nov 19 04:01 PM
Hidalgo Medina Manuel	Director	Nov 17 '25	Option Exercise	0.00	232	0	1,047	Nov 18 05:07 PM
Tariq Musa	Director	Nov 15 '25	Option Exercise	0.00	250	0	7,975	Nov 17 05:30 PM

Open in Screener

XGN

Exagen Inc

Apr 02 • 04:00PM ET

3.06

+0.05 1.66 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN ONC MYGN QGEN NTRA GH VCYT CDNA PRPO FLGT

| Held by: VTI VXF IWC DFAS DFMC DFAC DFSU DCOR

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	36.09%	Shs Outstand	22.91M	Perf Week	9.68%
Market Cap	73.60M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.69%	Shs Float	15.37M	Perf Month	-14.76%
Enterprise Value	69.05M	PEG	-	EPS next Q	-0.22	Inst Own	48.62%	Short Float	7.44%	Perf Quarter	-49.67%
Income	-19.95M	P/S	1.11	EPS this Y	25.81%	Inst Trans	10.63%	Short Ratio	2.49	Perf Half Y	-72.13%
Sales	66.58M	P/B	4.02	EPS next Y	36.85%	ROA	-38.15%	Short Interest	1.14M	Perf YTD	-49.67%
Book/sh	0.76	P/C	2.28	EPS next 5Y	44.97%	ROE	-147.85%	52W High	12.23 -74.98%	Perf Year	-30.93%
Cash/sh	1.34	P/FCF	-	EPS past 3/5Y	30.65% 6.84%	ROIC	-47.38%	52W Low	2.59 18.15%	Perf 3Y	25.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.47% 9.66%	Gross Margin	58.28%	Volatility	7.68% 8.65%	Perf 5Y	-82.51%
Dividend TTM	-	EV/Sales	1.04	EPS Y/Y TTM	-10.83%	Oper. Margin	-21.13%	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.22	Sales Y/Y TTM	19.65%	Profit Margin	-29.97%	RSI (14)	46.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	2.89%	SMA20	1.97%	Beta	1.98	Target Price	9.50
Payout	-	Debt/Eq	1.59	Sales Q/Q	21.79%	SMA50	-10.11%	Rel Volume	0.23	Prev Close	3.01
Employees	216	LT Debt/Eq	1.41	Earnings	Mar 10 BMO	SMA200	-57.95%	Avg Volume	459.26K	Price	3.06
IPO	Sep 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.43% 0.37%	Trades		Volume	105,526	Change	1.66%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-25	Initiated	B. Riley Securities	Buy	$15
Jul-30-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$12
Jul-23-25	Initiated	Craig Hallum	Buy	$12
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Show Previous Ratings

Mar-10-26 05:01PM	Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments (GuruFocus.com)
09:20AM	Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Mar-09-26 05:35PM	Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-03-26 09:00AM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:25PM	Loading…
Feb-25-26 07:25PM	Agilent Technologies (A) Lags Q1 Earnings and Revenue Estimates (Zacks)
Feb-24-26 09:00AM	Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 (GlobeNewswire)
Jan-11-26 03:00PM	Exagen Inc. Announces Select Preliminary 2025 Financial Results (GlobeNewswire)
Nov-11-25 09:00AM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Nov-04-25 04:08PM	Exagen Inc (XGN) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) -8.96%
09:10AM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Q3 2025 Results (GlobeNewswire)
Nov-03-25 08:06AM	What To Expect From Exagen Inc (XGN) Q3 2025 Earnings (GuruFocus.com)
Oct-23-25 09:15AM	Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence (GlobeNewswire)
Oct-21-25 04:05PM	Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
10:30PM	Loading…
Aug-12-25 10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-06-25 04:05PM	Exagen Inc. to Participate in Third Quarter Investor Conferences (GlobeNewswire)
Jul-29-25 09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +14.34%
08:00AM	Exagen Inc. Reports Strong Q2 2025 Results (GlobeNewswire)
Jul-28-25 09:39AM	Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-24-25 09:09AM	Exagen Inc. (XGN): A Bull Case Theory (Insider Monkey)
08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-25 04:05PM	Exagen Inc. Appoints Chas McKhann to Board of Directors (GlobeNewswire)
Jul-15-25 04:05PM	Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jun-23-25 09:00AM	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics (GlobeNewswire)
May-09-25 04:05PM	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire) -7.31%
May-08-25 08:30AM	Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire) -9.81%
May-07-25 04:05PM	Exagen Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.39%
May-06-25 03:03AM	Exagen Inc (XGN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Wins Amidst ... (GuruFocus.com)
01:18AM	Q1 2025 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
04:51PM	Loading…
May-05-25 04:51PM	Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume (GlobeNewswire)
May-02-25 09:36AM	Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-28-25 09:00AM	Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors (GlobeNewswire) +7.09%
Apr-26-25 03:31AM	Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability (Seeking Alpha)
Apr-21-25 04:05PM	Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +9.26%
Mar-12-25 03:04AM	Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
12:10AM	Q4 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 09:15AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +18.25%
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-25-25 04:05PM	Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Feb-05-25 06:38AM	Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? (Zacks) +6.18%
Feb-04-25 04:05PM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) +29.38%
Jan-12-25 12:00PM	Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results (GlobeNewswire)
Dec-12-24 09:00AM	Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD (GlobeNewswire) +12.02%
Nov-14-24 04:30PM	Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform (GlobeNewswire) +5.45%
Nov-13-24 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
02:09AM	Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com)
12:51AM	Q3 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 09:25AM	Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.06%
Nov-11-24 07:25AM	Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:05PM	Exagen to Announce Third Quarter 2024 Results on November 12, 2024 (GlobeNewswire)
Oct-21-24 04:05PM	Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence (GlobeNewswire)
Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ABALLI JOHN	President and CEO	Mar 03 '26	Sale	3.62	15,698	56,827	687,299	Mar 04 03:00 PM
ABALLI JOHN	President and CEO	Feb 24 '26	Sale	3.61	11,430	41,262	702,997	Feb 25 07:11 PM
Black Jeffrey G.	Chief Financial Officer	Feb 24 '26	Sale	3.61	1,584	5,718	267,442	Feb 25 07:11 PM
ABALLI JOHN	President and CEO	Oct 16 '25	Sale	11.82	31,787	375,598	714,427	Oct 20 05:20 PM
Black Jeffrey G.	Chief Financial Officer	Sep 02 '25	Sale	9.79	20,466	200,362	269,026	Sep 04 07:40 PM

CSTL

VCYT

BDSX

LH

SERA

PSNL

NTRA

DGX

CELC

RDNT

FTRE

GH

XGN

Upgrade your Finviz experience